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A B S T R A C T
Background
The central venous catheter (CVC) is a device used for many functions, including monitoring haemodynamic indicators and admin-
istering intravenous medications, fluids, blood products and parenteral nutrition. However, as a foreign object, it is susceptible to
colonisation by micro-organisms, which may lead to catheter-related blood stream infection (BSI) and in turn, increased mortality,
morbidities and health care costs.
Objectives
To assess the effects of skin antisepsis as part of CVC care for reducing catheter-related BSIs, catheter colonisation, and patient mortality
and morbidities.
Search methods
InMay 2016we searched:TheCochraneWounds SpecialisedRegister; TheCochraneCentral Register ofControlledTrials (CENTRAL)
(The Cochrane Library); Ovid MEDLINE (including In-Process & Other Non-Indexed Citations and Epub Ahead of Print); Ovid
EMBASE and EBSCO CINAHL Plus. We also searched clinical trial registries for ongoing and unpublished studies. There were no
restrictions with respect to language, date of publication or study setting.
Selection criteria
We included randomised controlled trials (RCTs) that assessed any type of skin antiseptic agent used either alone or in combination,
compared with one or more other skin antiseptic agent(s), placebo or no skin antisepsis in patients with a CVC in place.
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Data collection and analysis
Two authors independently assessed the studies for their eligibility, extracted data and assessed risk of bias. We expressed our results in
terms of risk ratio (RR), absolute risk reduction (ARR) and number need to treat for an additional beneficial outcome (NNTB) for
dichotomous data, and mean difference (MD) for continuous data, with 95% confidence intervals (CIs).
Main results
Thirteen studies were eligible for inclusion, but only 12 studies contributed data, with a total of 3446 CVCs assessed. The total number
of participants enrolled was unclear as some studies did not provide such information. The participants were mainly adults admitted to
intensive care units, haematology oncology units or general wards. Most studies assessed skin antisepsis prior to insertion and regularly
thereafter during the in-dwelling period of the CVC, ranging from every 24 h to every 72 h. The methodological quality of the included
studies was mixed due to wide variation in their risk of bias. Most trials did not adequately blind the participants or personnel, and
four of the 12 studies had a high risk of bias for incomplete outcome data.
Three studies compared different antisepsis regimens with no antisepsis. There was no clear evidence of a difference in all outcomes
examined, including catheter-related BSI, septicaemia, catheter colonisation and number of patients who required systemic antibiotics
for any of the three comparisons involving three different antisepsis regimens (aqueous povidone-iodine, aqueous chlorhexidine and
alcohol compared with no skin antisepsis). However, there were great uncertainties in all estimates due to underpowered analyses and
the overall very low quality of evidence presented.There were multiple head-to-head comparisons between different skin antiseptic
agents, with different combinations of active substance and base solutions. The most frequent comparison was chlorhexidine solution
versus povidone-iodine solution (any base). There was very low quality evidence (downgraded for risk of bias and imprecision) that
chlorhexidinemay reduce catheter-related BSI compared with povidone-iodine (RR of 0.64, 95%CI 0.41 to 0.99; ARR 2.30%, 95%CI
0.06 to 3.70%).This evidence came from four studies involving 1436 catheters.None of the individual subgroup comparisons of aqueous
chlorhexidine versus aqueous povidone-iodine, alcoholic chlorhexidine versus aqueous povidone-iodine and alcoholic chlorhexidine
versus alcoholic povidone-iodine showed clear differences for catheter-related BSI or mortality (and were generally underpowered).
Mortality was only reported in a single study.
There was very low quality evidence that skin antisepsis with chlorhexidine may also reduce catheter colonisation relative to povidone-
iodine (RR of 0.68, 95% CI 0.56 to 0.84; ARR 8%, 95% CI 3% to 12%; ; five studies, 1533 catheters, downgraded for risk of bias,
indirectness and inconsistency).
Evaluations of other skin antiseptic agents were generally in single, small studies, many of which did not report the primary outcome
of catheter-related BSI. Trials also poorly reported other outcomes, such as skin infections and adverse events.
Authors’ conclusions
It is not clear whether cleaning the skin around CVC insertion sites with antiseptic reduces catheter related blood stream infection
compared with no skin cleansing. Skin cleansing with chlorhexidine solution may reduce rates of CRBSI and catheter colonisation
compared with cleaning with povidone iodine. These results are based on very low quality evidence, which means the true effects may
be very different. Moreover these results may be influenced by the nature of the antiseptic solution (i.e. aqueous or alcohol-based).
Further RCTs are needed to assess the effectiveness and safety of different skin antisepsis regimens in CVC care; these should measure
and report critical clinical outcomes such as sepsis, catheter-related BSI and mortality.
P L A I N L A N G U A G E S U M M A R Y
Skin antisepsis for reducing central venous catheter-related infections
Review Question
We reviewed the evidence about whether using antiseptic treatments on people’s skin helps reduce infections related to central venous
catheters (CVCs).
Background
Central venous catheters (CVCs) are thin, flexible tubes that are inserted through the skin into a large vein, often in the arm or chest.
The tube can then be used to give fluids, medicine and nutrition to chronically and critically ill patients. However, CVCs pose a
significant risk of infection by providing a way for micro-organisms (germs) to spread into the body at the point where the catheter
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is inserted. In order to try to reduce catheter-related infections, healthcare staff frequently use antiseptic solutions to clean the skin
around the catheter insertion site, both prior to insertion and whilst the catheter is in place. In this review, we summarise the evidence
of the benefits and harms of using antiseptics on the skin, and the effects of different antiseptic solutions.
Search date
We searched multiple medical databases in May 2016.
Study characteristics
In May 2016 we searched medical databases to find randomised controlled trials looking at the use of skin antiseptics in people with
CVCs.We included 13 studies in this review, although only 12 studies contributed data for a total of 3446 CVCs. The study participants
were mainly adults in intensive care units or other specialist hospital units. We reported our findings in terms of the number of catheters,
as some studies did not provide the number of patients assessed, and some patients had more than one CVC.One study was funded
by a national research body, five studies were funded in whole or in part by at least a pharmaceutical company, and in the remaining
seven studies funding sources were not stated.
Key results
Three studies examined the effect of cleansing versus no cleansing, and found no clear evidence of differences in blood infections,
infections in the catheter and need for antibiotics between patients who received cleansing compared to those who did not. Chlorhexidine
solution may reduce blood infections associated with the catheter compared with povidone-iodine solution (reducing the infection
rate from 64 cases per 1000 patients with a CVC with povidone iodine to 41 cases of infection per 1000 with chlorhexidine). This
translates into the need to treat 44 people to avoid one additional bloodstream infection. Chlorhexidine solution may (compared with
povidone iodine solution) also reduce the presence of infectious organisms within the catheter (reduced from 240 infected catheters
per 1000 people to 189 infected catheters per 1000 people). It is unclear whether antiseptic skin cleansing influences mortality rates as
only one study reported this and although similar death rates were observed with povidone iodine and chlorhexidine, small numbers
mean a difference cannot be ruled out.
Quality of evidence
The overall quality of evidence was poor due to flaws in the way the studies were designed, small study sizes, inconsistency of the results
between the included studies and the nature of the outcomes reported. These flaws have reduced our confidence in the results of the
studies. This means we cannot be certain whether cleaning the skin around CVC insertion sites with antiseptic reduces catheter-related
blood stream infection and other harmful effects, such as overall blood infections and mortality compared with no skin cleansing.
Cleansing with chlorhexidine solution may be more effective than povidone iodine but the quality of the evidence was very low.
3Skin antisepsis for reducing central venous catheter-related infections (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Chlorhexidine compared to povidone- iodine for patients with a central venous catheter
Patient or population: pat ients with a central venous catheter
Settings: hospital inpat ients
Intervention: chlorhexidine
Comparison: povidone-iodine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Povidone- iodine Chlorhexidine
Catheter-related BSI - over-
all comparison between
chlorhexidine and povi-
done-iodine
(during in-pat ient stay)
Study populat ion RR 0.64
(0.41 to 0.99)
1436
(4 RCTs)
⊕©©©
Very lowb,c
64 per 1000 41 per 1000
(26 to 63)
Moderatea
46 per 1000 29 per 1000
(19 to 45)
Catheter-related BSI - sub-
group: chlorhexidine in
aqueous solut ion versus
povidone-iodine in aqueous
solut ion
Study populat ion RR 0.64
(0.32 to 1.28)
452
(2 RCTs)
⊕©©©
Very lowc,d
86 per 1000 55 per 1000
(28 to 110)
Moderate
84 per 1000 54 per 1000
(27 to 108)
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Catheter-related BSI - sub-
group: chlorhexidine in alco-
hol versus povidone-iodine
in aqueous solut ion
Study populat ion RR 0.77
(0.39 to 1.53)
503
(2 RCTs)
⊕©©©
Very lowc,d
70 per 1000 54 per 1000
(27 to 108)
Moderate
69 per 1000 53 per 1000
(27 to 106)
Catheter-related BSI - sub-
group: chlorhexidine in alco-
hol versus povidone-iodine
in alcohol
Study populat ion RR 0.4
(0.13 to 1.24)
481
(1 RCT)
⊕⊕⊕©
Moderatec
42 per 1000 17 per 1000
(5 to 52)
Moderate
42 per 1000 17 per 1000
(5 to 52)
Primary BSI or clinical sep-
sis
No studies under this comparison assessed this out-
come.
All-cause mortal-
ity - Chlorhexidine in aque-
ous solut ion versus povi-
done-iodine in aqueous so-
lut ion
Clinical assessment
Study populat ion RR 1.15
(0.72 to 1.83)
213
(1 RCT)
⊕⊕©©
lowc,e
236 per 1000 271 per 1000
(170 to 432)
Moderate
236 per 1000 271 per 1000
(170 to 432)
All-cause
mortality - Chlorhexidine in
alcohol versus povidone-io-
dine in aqueous solut ion
Study populat ion RR 0.8
(0.48 to 1.34)
222
(1 RCT)
⊕⊕©©
lowc,e
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Clinical assessment
236 per 1000 189 per 1000
(113 to 316)
Moderate
236 per 1000 189 per 1000
(113 to 316)
Mortality attributable the
CVC-related infect ions.
No studies under this comparison assessed this out-
come.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
BSI: bloodstream infect ion; CI: Conf idence interval.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a ’Moderate risk’ was calculated f rom the median control event rate for each outcome.
bThree of the four included studies had unclear risks of bias in allocat ion concealment, and all had high risks of bias in
blinding of part icipants and personnel.
cThe 95% CI was wide.
dThere was an overall very serious concern on risk of bias that resulted in downgrading of two levels: both studies had unclear
risk of bias under allocat ion concealment and high risk of bias under blinding of part icipants and personnel, and one study
had serious unit of analysis issue as the outcome was reported using catheters as the unit , and the number of catheters
analysed exceeded the number of part icipants by over 50%, ref lect ing that fact that some patients received mult iple catheters
during the study, which could have seriously af fected the ef fect est imate.
eThe single study had unclear risk in allocat ion concealment, high risk in blinding of pat ients and personnel which might give
rise to performance bias, which in turn might af fect the risk of mortality, as well as high risk of attrit ion bias.
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B A C K G R O U N D
Please refer to Appendix 1 for a glossary of terms (lay definitions
in the context of this review only).
Description of the condition
The concept of central venous catheterisation was first introduced
in the early part of the last century by Bleichroder, Forssmann,
Duffy and Authaniac, after Bleichroder reportedly inserted the
first central venous catheter (CVC) in a human in 1905 (Puri
2009). In the past four decades, the use of the CVC has become
important in themanagement ofmany critically and chronically ill
patients. Insertion of a CVC provides secure vascular access for the
administration of intravenous medications, fluids, blood products
and parenteral nutrition. It also serves as an essential conduit for
blood sampling, haemodynamic monitoring, renal replacement
therapy and plasmapheresis.
It is estimated that 5 million CVCs are inserted every year in the
United States and 200,000 each year in the UK (Worthington
2005). One of the major problems associated with the use of
CVCs is colonisation bymicro-organisms that could result in local
or systemic infection. Research has shown that infectious com-
plications associated with CVCs cause significant morbidity and
mortality, with considerable costs to the healthcare system (CDC
2011; Cicalini 2004). In the USA, approximately 80,000 reported
cases of CVC-associated blood stream infections (BSIs) occur in
intensive care units (ICUs) every year; this number more than
triples when considering the entire hospital system (CDC 2011).
Although the exact mortality attributable to these BSIs remains
unclear, reports have cited figures up to 35% (CDC 2011). The
associated cost incurred due to BSIs is considerable, including
costs of additional medication, nursing time and increased length
of hospital stay. The total annual cost of caring for patients with
CVC-associated BSIs in the USA alone is estimated to range any-
where from USD 296 million to USD 2.3 billion (CDC 2011).
Micro-organisms colonise the CVCs and gain access to the blood
stream of the patients via three main routes (CDC 2011; Cicalini
2004; Pagani 2008):
• External surface of CVC through contaminated insertion
site
• Internal surface of CVC through contamination of catheter
hubs, injection ports and lines; usually by the hands of
healthcare workers or patients
• Contaminated intravenous drugs, infusates and nutritional
preparations.
For short-term CVCs, investigators have proposed colonisation
from the skin to the external surface of the CVCs as the major
route of infection, while for long-term CVCs, the internal sur-
face route becomes increasingly important, as the micro-organ-
isms gain access to the internal surface as a result of contamination
from repeated handling of the CVCs (Cicalini 2004).
Description of the intervention
A number of evidence-based guidelines have been developed in
recent years aimed at reducing CVC-associated BSIs. Important
measures recommended by two of the major guidelines include
the following (CDC 2011; Pratt 2007):
• Staff education
• Quality assurance: systematically monitoring compliance to
the established guidelines and evaluating issues relating to
compliance
• Hand hygiene
• The use of aseptic technique during insertion and use of
CVCs
• Effective skin antisepsis at the insertion site
• Maximum sterile barrier precautions (i.e. wearing sterile
gloves, sterile gown, a cap and a mask and using a large sterile
drape)
• Use of subclavian vein as the preferred site of insertion
rather than the internal jugular or femoral veins, as this has been
shown to reduce infectious, mechanical and thrombotic
complications (Hamilton 2007)
• The use of antimicrobial or antiseptic impregnated CVCs.
Effective skin antisepsis throughout the in-dwelling period of the
cathetermay preventmicrobial contaminationof the insertion site,
thus delaying or reducing the risk of catheter colonisation and the
subsequent development of infective complications. Given that
insertion site contamination leads to colonisation on the external
catheter surface and infection, one would expect skin antisepsis
to have some impact on reducing BSIs, especially with short-term
CVCs.
Pioneering work by Pasteur, Semmelweis and Lister laid the foun-
dation for the practice of antisepsis in medicine (Bankston 2005;
Bynum 2008; Nuland 2003). Antisepsis is defined as the preven-
tion of infection by inhibiting the growth of causative micro-or-
ganisms, while antiseptics are antimicrobial substances capable of
producing antisepsis (Taber 2016). An ideal antiseptic agentwould
need to be immediately and persistently effective when applied to
living tissues, including when a small amount of blood is present,
and to be effective against all pathogenic bacteria, viruses, fungi,
protozoa, tubercle bacilli and bacterial spores (Taber 2016). At the
same time it should be non-toxic to living tissue, hypoallergenic
and safe to use repetitively on all parts of the body (Edwards 2008;
Hardin 1997). Human skin naturally has abundant microbiolog-
ical flora which include resident (i.e. colonising) flora and tran-
sient (i.e. contaminating or non-colonising) flora. Resident flora
tend to inhabit deeper layers of the skin and therefore are not
readily removed by the mechanical action of washing with soap
and water. In contrast, transient flora are not consistently present
in most people and can usually be removed by mechanical action
(Larson 1995; Ryan 2004). Both resident and transient flora are
implicated in the pathogenesis of CVC-associated infections, thus
effective skin antisepsis may require not only mechanical removal
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but also the chemical killing and inhibition of both the resident
and transient flora of the human skin (Edwards 2008).
How the intervention might work
There is a large number of antiseptic agents available and three
are considered particularly important in skin antisepsis: chlorhexi-
dine, iodine and alcohol. All three agents have a broad spectrum of
activity against gram positive, gram negative, aerobic and anaero-
bic bacteria, enveloped viruses such as human immunodeficiency
virus (HIV), herpes simplex virus (HSV) and cytomegalovirus
(CMV), as well as fungi, although they differ in their effects against
tubercle bacilli and bacterial spores. We summarise their charac-
teristics here:
• Chlorhexidine, which is available mostly as chlorhexidine
gluconate and less commonly as chlorhexidine acetate or
hydrochloride (Martindale 2016), exercises its antimicrobial
action chiefly by causing a disruption of microbial cell
membranes. Its activity against tubercle bacilli and bacterial
spores is limited (Larson 1995; Russell 1986). Chlorhexidine
gluconate has an intermediate onset of effect, which is reported
to be minimally affected by organic materials such as blood, pus
or sputum. It also appears to cause relatively low level of skin
irritation and has little allergenic potential. However, its activity
is pH dependent, and its effect is known to be compromised by
many substances, including those used in natural soaps (Larson
1995; Martindale 2016).
• Iodine and iodophors exert their antimicrobial effects
through chemical destruction of the microbial cell wall and
cellular contents. They are effective against tubercle bacilli and
bacterial spores. They kill bacteria within seconds to minutes but
are rapidly inactivated in the presence of organic materials such as
blood, pus or sputum. There have been reports of frequent skin
irritation, allergic reactions and systemic toxicity in susceptible
individuals (Edwards 2008; Hardin 1997; Larson 1995).
• Alcohols are available as either ethyl (ethanol), normal-
propyl (n-propyl) or isopropyl alcohol for use as antiseptic
agents. Alcohols derive their antimicrobial activity from
denaturation of cellular proteins. They are effective against
tubercle bacilli but less so against bacterial spores. Alcohols have
a rapid onset of action, but they lose their antimicrobial effects
very quickly. Importantly for this review, they are often
combined with other agents such as chlorhexidine gluconate or
iodine to achieve optimal antisepsis. Alcohols are also poor
cleaning agents, and their use is usually not recommended when
significant amounts of blood or dirt are present. There have been
reports of excessive skin drying and discomfort following
application (Larson 1995; Martindale 2016).
Other antiseptic agents include the following (Larson 1995;
Martindale 2016):
• Triclosan
• Hexachlorophene
• Chloroxylenol
• Quarternary ammonium compounds such as cetrimide and
benzalkonium chloride
• Octenidine dihydrochloride
• Phenolic or carbolic acid compounds
• Hydrogen peroxide.
Why it is important to do this review
A meta-analysis showed that using chlorhexidine gluconate for
catheter site care reduced the risk of catheter-related BSIs by
49% when compared with povidone iodine (Chaiyakunapruk
2002). However, the meta-analysis only evaluated chlorhexidine
gluconate and povidone-iodine as skin antiseptics, and some stud-
ies within it assessed a combination of arterial catheters as well
as central and peripheral venous catheters. Some uncertainties re-
main regarding the best agent, or combination of agents, for use
as skin antisepsis for CVCs alone; the optimal interval between
application of antiseptics as well as the best method for applying
these agents. Examination of the latest National Healthcare Sa-
fety Network report, which superseded the National Nosocomial
Infections Surveillance (NNIS 2004), revealed that the CVC-as-
sociated BSI rate in different ICUs in the USA ranges from 1.0
to 5.6 BSI per 1000 CVC-days (Edwards 2008). These figures
compare favourably with the previous NNIS figures of 2.7 to 7.4
BSI per 1000 CVC-days (NNIS 2004). The observed improve-
ment in CVC-associated BSI rate is probably multifactorial in na-
ture, but the recent educational and awareness campaigns about
nosocomial infections and the implementation of infection con-
trolmeasures inmany hospitals in theUSAmay have played a role.
The impact of different skin antisepsis regimens in the presence
of comprehensive infection control measures and lower baseline
BSI rates remains unclear. Furthermore, the availability of new
studies using different skin antiseptic preparations and the contin-
uing emergence of drug resistant micro-organisms necessitates a
systematic review to aid clinical decision-making and to highlight
future research needs (O’Grady 2002; Parienti 2004; Pratt 2007).
O B J E C T I V E S
To assess the effects of skin antisepsis around central venous
catheter sites, on rates of catheter-related BSIs, catheter colonisa-
tion, and patient mortality and morbidities.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We included randomised controlled trials (RCTs) and cluster
RCTs comparing one skin antiseptic regimen (a single agent or
a combination of agents) with another regimen (a single agent
or a combination of agents, placebo or no antisepsis). We ex-
cluded cross-over studies due to the possible contaminating ef-
fect of one intervention over another. We also excluded studies
assessing CVCs for haemodialysis, as this is covered by another
Cochrane review (McCann 2010).
Types of participants
We included studies involving adults and children cared for in a
hospital setting (in adult or paediatric wards or ICUs) with any
underlying illness and a CVC inserted for any reason during the
study period. Studies that enrolled a patient more than once were
acceptable provided that the enrolment took place in separate hos-
pital admissions. We excluded studies conducted in neonatal set-
tings, for example in a neonatal intensive care unit (NICU), as the
types of catheters used, the insertion site and techniques, the pos-
sible complications as well as the risk factors for sepsis are different
compared with those in older children and adults (Trieschmann
2007).
Types of interventions
Intervention
The use of any skin antiseptic regimen (a single agent or a combi-
nation of agents) used for cleansing the skin around CVC inser-
tion sites.
Comparisons
Adifferent skin antisepsis regimen (a single agent or a combination
of agents), placebo or no skin antisepsis for CVC insertion sites.
We required that the selection, insertion, use, maintenance and
removal of CVCs in the intervention and comparison groups fol-
lowed the standard protocol of the hospital setting in the study.
The skin antisepsis regimen had to be the only systematic differ-
ence between comparison groups (i.e., not catheter material or
concurrent CVC-related antiseptic measures).
We accepted the duration of the studies as variously specified by
the authors. We did not place any limit on the minimum and
maximum duration of the follow-up period for each study.
Types of outcome measures
Primary outcomes
Number of patients with CVC-related blood stream infection
(BSI)
• Catheter-related BSI confirmed by laboratory
• Primary BSI or clinical sepsis.
We present the criteria for the diagnosis of CVC-related BSI in
Appendix 2 (Pagani 2008).
Mortality
• All-cause mortality
• Mortality attributable to CVC-related infections.
We included suitable studies using other definitions of CVC-re-
lated and associated infections, provided the authors justified their
definitions with valid sources.
Secondary outcomes
• Number of patients with insertion site infection, either
microbiologically documented (i.e. exudates at catheter insertion
site yield a micro-organism with or without concomitant BSI) or
clinically documented (i.e. erythema or induration within 2 cm
of the catheter insertion site in the absence of associated BSI and
without accompanying purulence) (Pagani 2008)
• Number of patients with catheter colonisation, as defined
by the study authors using well-accepted definitions such as a
significant growth of micro-organism (more than 15 colony-
forming units (CFU)) from the catheter tip, subcutaneous
segment or catheter hub in the absence of clinical signs of
infection (Pagani 2008)
• Number of drug-resistant organisms from cultures,
including insertion site cultures, catheter cultures and blood
cultures
• Number of adverse events associated with the use of
antiseptic agents, including skin irritation, contact dermatitis,
systemic allergic reaction and anaphylaxis
• Antibiotic usage during hospitalisation
• Length of hospitalisation, either ICU stay or overall
hospital stay
• Cost of care, including cost of the antiseptic agent and the
cost of treating any adverse effects
• Quality of life, measured using validated tools.
Search methods for identification of studies
Electronic searches
We searched the following databases for relevant RCTs:
• The Cochrane Wounds Specialised Register (searched 23
May 2016);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library) (2016, Issue 4);
9Skin antisepsis for reducing central venous catheter-related infections (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Ovid MEDLINE (including In-Process & Other Non-
Indexed Citations and Epub Ahead of Print) (1946 to 23 May
2016);
• Ovid EMBASE (1974 to 23 May 2016);
• EBSCO CINAHL Plus (1937 to 23 May 2016).
We used the search strategy in Appendix 3 to search the Cochrane
Central Register of Controlled Trials (CENTRAL). We adapted
this strategy for Ovid MEDLINE, Ovid EMBASE and EBSCO
CINAHL Plus which can be found in Appendix 4, Appendix 5
andAppendix 6, respectively.We combined theMEDLINE search
with theCochraneHighly Sensitive Search Strategy for identifying
randomised trials in MEDLINE: sensitivity- and precision-max-
imising version (2011 revision) (Lefebvre 2011). We combined
the EMBASE search with the Ovid EMBASE filter developed
by the UK Cochrane Centre (Lefebvre 2011). We combined the
CINAHL searches with the trial filters developed by the Scottish
Intercollegiate Guidelines Network (SIGN 2015).
We searched the following trial registries for details of ongoing
clinical trials and unpublished studies.
• ClinicalTrials.gov (http://www.clinicaltrials.gov/).
• WHO International Clinical Trials Registry Platform (
http://apps.who.int/trialsearch/Default.aspx).
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/).
Searching other resources
We checked for further reports of eligible studies using the citation
lists of papers identified by the above strategies. We also scanned
references lists of relevant Cochrane reviews and guidelines and
contacted experts in the field.
Data collection and analysis
Selection of studies
Two review authors (NML, EOR) independently assessed the first
roundof search results for potentially relevant studies.We retrieved
in full those that appeared to meet the inclusion criteria, or where
this could not be determined, for further assessment. Two review
authors independently assessed the full papers retrieved, resolving
any disagreement with input from a third review author (NC).We
included the studies if they fulfilled the criteria for inclusion as
outlined above and if the amount of information contained in the
article enabled the extraction of outcome data for meta-analysis.
We screened publications for duplicate reports of the same trial
and contacted the trial authors for clarification when necessary.
If we confirmed a duplicate publication, we identified a primary
reference, but extracted unique data from all versions.
Data extraction and management
Two pairs of review authors (NAL and NML, PL and EOR) inde-
pendently extracted and coded all data for each included study us-
ing a pro forma designed specifically for this review. Each pair was
responsible for half of the total number of included studies. We
extracted the following information on each study: study design,
participants, setting, sample size, nature of intervention, compar-
ison, outcomes, methods (unit of allocation and analysis) and re-
sults. We screened for duplicate entries of patients, where possible,
by matching the initial number of patients recruited against the
total number along each step in the conduct of the study.
We found a discrepancy between the number of catheter and the
number of patients in most studies. This was due to multiple
catheters being inserted in some patients who were enrolled after
each insertion.Wewere unable to limit our analysis to one catheter
per participant as none of the studies provided the data in this
format.
We resolved any disagreement among the review authors by dis-
cussion and formulation of a consensus acceptable to all members
of the review team.
Assessment of risk of bias in included studies
Two authors (NAL and NML) independently assessed each in-
cluded study using the Cochrane tool for ’Risk of bias’ assessment
(Higgins 2011a). This tool addresses six specific domains.
1. Sequence generation
2. Allocation concealment
3. Blinding
4. Incomplete outcome data
5. Selective outcome reporting
6. Other issues (e.g. extreme baseline imbalance, design-
specific risks of bias such as recruitment in cluster for cluster-
RCT, block randomisation of unblinded trials or fraud).
We present detailed criteria on which we based our judgement in
Appendix 7. We assessed blinding and completeness of outcome
data for each outcome separately. We completed a ’Risk of bias’
table for each eligible study. We resolved any disagreement among
the review authors by discussion to achieve a consensus. We pre-
sented an overall assessment of the risk of bias using a ’Risk of bias
summary figure’, which presented all of the judgement in a cross-
tabulation of study by entry. This display of internal validity indi-
cated the weight the reader may give to the results of each study.
In addition, we assessed whether trials followed a standard proto-
col for all groups under study with regard to the insertion, use,
maintenance and removal of CVC, and regarding the concurrent
use of other antisepticmeasures such as antimicrobial impregnated
CVCs, antiseptic-soakeddressing andprophylactic antibiotics.We
referred to the study protocol, where available, for further details
if necessary. We made relevant remarks in the corresponding ’Risk
of bias’ table for each study if there were significant concerns in
this aspect.
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Measures of treatment effect
For dichotomous data, we used risk ratio (RR) to measure out-
come estimates of the same scale.We estimated the number needed
to treat for an additional beneficial outcome (NNTB) from the
pooled risk difference (RD) using an online NNTB calculator (
http://nntonline.net/visualrx/). For continuous data, we pooled
measures at a similar time point using the mean difference (MD).
Two studies reported the measure of variance as a standard error
(SE) or 95% confidence intervals (CI) (Humar 2000; Dettenkofer
2010). We obtained standard deviations (SD) for the above-men-
tioned studies from the SE using the formula SD = SE x square
root of the number of participants, and from the 95%CI using the
formula SD = square root of the number of participants x (upper
limit or CI − lower limit of CI)/3.92.
Unit of analysis issues
One potential unit of analysis issue that we had anticipated was
the issue that arose as a result of the studies using catheters, rather
than patients, as the unit of analysis in catheter-related outcomes
such as catheter-related BSI and catheter colonisation. Ideally, if
the study performed randomisation and analysis based on the par-
ticipants, and each participant had only one catheter evaluated,
adjustment for clustering would not have been necessary. How-
ever, if a study included multiple catheters per patient and clearly
stated so, we would have assessed whether the authors had under-
taken statistical adjustment to account for the effects of clustering
by using appropriate analysis models such as the ’generalised esti-
mating equation’ (GEE) model (Higgins 2011b). If investigators
hadmade adjustments for clustering, wewould have combined the
study with other studies in the meta-analysis. If they had not, or
if it was unclear whether there were adjustments made, we would
have assessed the number of catheters as well as participants in the
study. If the studies had also reported the number of participants
with events and the total number analysed, we would have only
reported the outcomes using the participants, rather than catheters
as the unit of analysis. However, if the study did not provide par-
ticipant-level data, we would not have been able to avoid the unit
of analysis issues. We would have acknowledged this as a major
limitation of the review in our discussion and undertaken sensi-
tivity analysis to assess the pooled results after excluding studies
with no adjustments for clustering.
However, in this review, none of the included studies provided
participant-level data for catheter-specific outcomes. As a result, we
could not adjust for the unit of analysis issue, nor couldwe perform
sensitivity analysis to assess the results with and without studies
with unadjusted unit of analysis issues. We have acknowledged
this in our discussion, as planned.
Another possible unit of analysis issue that could have arisen was
the effects of clustering that arose in cluster-RCTs in which ran-
domisation was performed at the unit, rather than the participant
level.However, we did not include any cluster-RCTs in this review.
Had we identified an eligible cluster-RCT (e.g. trial in which the
assignment to intervention or control group was made at the level
of the unit or ward rather than the individual), we would have
addressed the possible unit of analysis issues as follows.
First, we would have assessed whether the authors had made ad-
justments for the effects of clustering to account for non-inde-
pendence among the participants by using appropriate analysis
models such as the ’generalised estimating equation’ (GEE) model
(Higgins 2011b).
If investigators did not make adjustments for the effects of clus-
tering, we would have performed adjustment by multiplying the
SEs of the final effect estimates by the square root of the ’design
effect’, represented by the formula ’1 + (m − 1) x ICC’, where m
is the average cluster size (number of participants per cluster) and
ICC is the intracluster correlation. We would have determined the
average cluster sizem by dividing the total number of participants
by the total number of clusters. We would have used an assumed
ICC of 0.10, which has been proposed to be a realistic general
estimate based on previous similar studies (Campbell 2001). We
would also have combined the adjusted final effect estimates from
each trial with their SEs in our meta-analysis using the generic
inverse-variance methods, as stated in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b).
If it were impossible to find out whether trialists made adjustments
on the effect of clustering, we would still have included the studies
concerned in our meta-analysis using the effect estimates reported
by the authors, and performed sensitivity analyses to assess how
excluding those studies would affect the overall pooled estimates.
Dealing with missing data
We assessed whether there was a high attrition rate and whether an
intention-to-treat analysis was performed. To assess whether the
dropout rate was important, we inspected the absolute attrition
rate and the attrition rate in relation to the event rates for the inter-
vention and the comparison groups. If the absolute dropout rate
was 20% or more, we judged the study to be at high risk of bias
due to incomplete outcome data. If the dropout rate was lower
than 20%, we used a ’worst-case-scenario’ method for the primary
outcomes (Guyatt 1993). For instance, for an unfavourable out-
come such as catheter-related BSI or mortality, if the results of
a trial favoured the intervention group, we assumed all dropouts
from the intervention group to have developed the outcome, and
all dropouts from the comparison group to have not developed the
outcome. We then analysed to see if such an assumption changed
the direction of the results (e.g. from favouring the intervention
group to favouring the comparison group). If so, we considered
the dropout rate to be significant. We made the reverse assump-
tion when a trial favoured the comparison group, or when the
outcomes examined were favourable, such as survival or treatment
success.
11Skin antisepsis for reducing central venous catheter-related infections (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of heterogeneity
We assessed all the included studies in terms of their clinical and
methodological characteristics.
1. Baseline characteristics of the participants
2. Clinical settings of the studies (e.g. intensive care units,
oncology wards, renal units)
3. Co-interventions
4. Methodological quality (as detailed in the ’Risk of bias’
assessment, for example studies at high risk of bias are defined as
studies with unclear or no allocation concealment, and studies
where participants, caregivers or investigators are not blinded, or
where blinding is unclear)
5. Nature of intervention (comparison between one skin
antiseptic regimen and placebo as opposed to comparison of two
active regimens)
6. Outcome assessment and unit of analysis.
We visually inspected the forest plots for any evidence of hetero-
geneity of treatment effects.Weused the I2 statistic (Higgins 2003)
to measure inconsistency in the results, with a value of 50% or
greater indicating moderate to substantial statistical heterogeneity.
We found significant statistical heterogeneity in one analysis (
Analysis 4.4) and provided a plausible explanation the possible
reason for heterogeneity in the formof risk of attrition bias in some
included studies. We decided to still provide the pooled estimate
for this analysis and separated the studies based on the risk of
attrition bias in our pre-specified sensitivity analysis.
Assessment of reporting biases
We planned to screen for publication bias in our review using a
funnel plot if there were more than 10 studies included in the
analysis. If publication bias was implied by a significant asymmetry
of the funnel plot, we would have included a statement in our
results with a corresponding note of caution in our discussion. We
did not generate any funnel plot in this review as there were fewer
than 10 studies included in the analysis across all the comparisons
and outcomes.
Data synthesis
Weused ReviewManager software to performmeta-analysis of the
included studies (RevMan 2014).We used a fixed-effect model for
most of our analyses, as there was no substantial clinical and statis-
tical heterogeneity. For the outcomes with substantial clinical and
statistical heterogeneity that was not satisfactorily explained or re-
duced by subgroup analyses, we used a random-effects model that
took into account between-study variability within the analysis
and lessened the possibility of spurious inferences of significance
compared to the fixed-effect model. We used the Mantel-Haen-
szel method to analyse all the dichotomous outcomes, as we an-
ticipated relatively frequent events for most of our outcomes. For
continuous outcomes, we employed the inverse variance methods
using the effect measure of mean differences. In our assessment
of the effects of missing data, we compared our adjusted analysis
using the best- and worst-case scenarios to the completer analysis
as reported by the study authors.
When there were more than two arms evaluated in a study, for ex-
ample, aqueous chlorhexidine versus alcoholic chlorhexidine ver-
sus aqueous povidone-iodine, we set up separate pairwise com-
parisons as subgroups under the major comparison of chlorhex-
idine versus povidone-iodine, as follows: aqueous chlorhexidine
versus aqueous povidone-iodine; and alcoholic chlorhexidine ver-
sus aqueous povidone-iodine. In so doing, we halved the total
number of participants and events in the povidone-iodine group
to avoid double-counting.
Had we identified studies that assessed cost-effectiveness, we
planned to provide only a narrative review of their findings and
not directly compare costs in studies using different units of mea-
surement, due to the complexity of analysing cost-effectiveness if
different price-years were used.
Subgroup analysis and investigation of heterogeneity
In this review, we created subgroups of comparisons based on
the solution used, for example, a subgroup for chlorhexidine in
aqueous solution versus povidone iodine in aqueous solution, and
another subgroup for chlorhexidine in alcohol versus povidone-
iodine in aqueous solution.
Had data been available, we would have carried out the following
subgroup analyses:
1. Short term CVCs (less than 10 days) versus longer term
CVCs (10 days or more)
2. CVCs with antimicrobial modifications (antimicrobial
impregnation, cuffs, hubs) versus CVCs with no antimicrobial
modifications
3. Studies undertaken in paediatric patients versus adult
patients
4. Studies undertaken in different patient populations with
different levels of care (intensive care patients, oncology patients,
renal patients and patients in general medical or surgical wards)
5. Studies undertaken with co-interventions (e.g. sepsis
prevention bundle) versus studies done without co-interventions
6. Studies that used rigorous criteria (e.g. as outlined in Pagani
2008) for determining catheter-related infections versus studies
that used more liberal criteria.
Sensitivity analysis
We performed the following sensitivity analyses.
1. Best- and worst-case scenarios to assess the impact of
missing data, as described in the section ’Dealing with missing
data’.
2. Including and excluding studies with unclear and high risks
of selection bias, namely, studies with unclear or high risk for
random sequence generation, allocation concealment or both.
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Had sufficient data been available, we would have performed ad-
ditional sensitivity analyses to include and exclude studies with
methodological issues other than selection bias, such as a lack of
blinding to the participants, caregivers or investigators, or where
blinding was unclear.
’Summary of findings’ table
We created a ’Summary of findings’ table, which displayed seven
major outcomes in our review, using the web-based GRADEpro
software (http://gdt.guidelinedevelopment.org) (Schünemann
2011a). We used the eight GRADE considerations (study limita-
tions, consistency of effect, imprecision, indirectness and publi-
cation bias, large effect, plausible confounding and dose response
relationship) to assess the overall quality of the body of evidence
(Schünemann 2011b). In generating the ’Summary of findings’
table, we interpreted the median control group event rate for the
outcome as ’moderate risk’.
R E S U L T S
Description of studies
Results of the search
We identified 609 records from the initial search of the Cochrane
Wounds Group Specialised Register, CENTRAL, MEDLINE,
EMBASE and CINAHL. We performed additional searches from
relevant published studies and identified two further studies that
appeared to be relevant. After removing duplicates, there were 574
records. Of these, 107 articles appeared to be relevant after we in-
spected the titles. We evaluated the abstracts and if necessary, the
full text of the articles, excluding 84 of the 107 records, including
one duplicate publication of another excluded study. Of the re-
maining 23 articles, one was an ongoing study, and we could not
fully assess six as we are still awaiting their full texts or further in-
formation from the authors. Ultimately, 16 articles describing 13
studies were available and met our inclusion criteria. Among these
16 articles, three were additional publications relating to three in-
cluded studies. The flow diagram of the studies from the initial
search to the meta-analysis is shown in Figure 1. We describe all
the included studies in theCharacteristics of included studies table
and note the reasons for excluding the others in the Characteristics
of excluded studies table.
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Figure 1. Study flow diagram.
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Included studies
We included 13RCTs, conducted in eight countries, including the
USA (four studies), France (two studies), and Canada, Germany,
Iran, Japan, Spain, Switzerland and Finland (1 study each). Ten
trials were single centre RCTs and three were multicentre RCTs
(Dettenkofer 2010; Humar 2000; Yasuda 2013) The number of
patients recruited ranged from 50 (with 50 CVCs) in Sadowski
1988 to 420 (with 998 CVCs) in Vallés 2008. Mimoz 1996,
Mimoz 2007 and Yasuda 2013 did not report the number of
participants. Prager 1984 recruited children (n = 3) in addition
to adults (in this case, n = 159), while Sadowski 1988 recruited
children and adolescent from 10 weeks to 15 years of age. All
studies included participants of both sexes.
Six studies recruited patients from the medical/surgical ICUs
(Maki 1991; Mimoz 1996; Mimoz 2007; Vallés 2008; Tuominen
1981; Yasuda 2013), two studies recruited patients who were ei-
ther pre- or post-cardiac surgery (Levy 1988; Yousefshahi 2013),
one study enrolled patients from a burns unit (Sadowski 1988),
one from haematology and surgical units (Dettenkofer 2010) and
the remaining three studies were conducted hospital-wide, which
included intensive-care and non intensive-care patients (Humar
2000; Langgartner 2004; Prager 1984). The average duration of
catheterisation, where reported, varied from 2 to 21.1 days (range
1 to > 30 days).
There were ten basic comparisons between two or three arms in
the included studies, with subgroups based on type of solution in
two comparisons.
• Comparison 1: povidone-iodine (in aqueous solution)
versus no skin antisepsis (Prager 1984).
• Comparison 2: chlorhexidine (in aqueous solution) versus
no skin antisepsis (Tuominen 1981).
• Comparison 3: alcohol versus no skin antisepsis (Sadowski
1988).
• Comparison 4: chlorhexidine versus povidone-iodine
(Humar 2000; Maki 1991; Mimoz 2007; Vallés 2008; Yasuda
2013). The specific subgroups for this comparison are listed
below based on the different preparations of chlorhexidine and/
or povidone-iodine:
◦ Chlorhexidine in aqueous solution versus povidone-
iodine in aqueous solution (Maki 1991; Vallés 2008).
◦ Chlorhexidine in alcohol versus povidone-iodine in
aqueous solution (Humar 2000; Vallés 2008).
◦ Chlorhexidine in alcohol versus povidone-iodine in
alcohol (Mimoz 2007).
◦ Chlorhexidine in alcohol versus povidone-iodine (base
solution unknown) (Yasuda 2013).
Among the studies included in this comparison, two (Vallés 2008;
Yasuda 2013) carried out three-arm comparison. Vallés 2008 com-
pared 2% chlorhexidine in aqueous solution (group 1), 0.5%
chlorhexidine in alcohol (group 2) and 10% povidone-iodine in
aqueous solution (group 3), while Yasuda 2013 compared 1%
chlorhexidine in alcohol (group 1), 0.5% chlorhexidine in alcohol
(group 2) and 10% povidone-iodine (base solution unknown).
Because the authors of Yasuda 2013 did not specify the base so-
lution for the povidone-iodine group, we could not include this
study in any subgroup in our meta-analysis.
• Comparison 5: chlorhexidine (aqueous) versus alcohol
(Maki 1991).
• Comparison 6: povidone-iodine versus alcohol.
◦ Povidone-iodine in aqueous solution versus alcohol
(Maki 1991).
◦ Povidone-iodine-impregnated adherent film versus
alcohol (Levy 1988).
• Comparison 7: alcohol versus octenidine in alcohol
(Dettenkofer 2010).
• Comparison 8: chlorhexidine (in alcohol) plus povidone-
iodine (in aqueous solution) versus chlorhexidine in alcohol
(Langgartner 2004).
• Comparison 9: chlorhexidine (in alcohol) plus povidone-
iodine (in aqueous solution) versus povidone-iodine (in aqueous
solution) (Langgartner 2004).
• Comparison 10: Sanosil (hydrogen peroxide and silver)
versus water as adjunct to chlorhexidine 2% aqueous bath plus
povidone-iodine 10% aqueous scrub (Yousefshahi 2013).
In terms of the timing of intervention, most studies assessed skin
antisepsis prior to insertion and regularly thereafter during the in-
dwelling period of the catheters, ranging from every 24 h to every
72 h. Three studies evaluated the skin antisepsis intervention only
prior to catheter insertion (Levy 1988; Yasuda 2013; Yousefshahi
2013), and one study examined skin antisepsis prior to removal
of the catheters (Sadowski 1988). Maki 1991 and Mimoz 1996
evaluated central venous as well as arterial catheters, although only
Maki 1991 provided a separate report of patients receiving CVCs
for the outcomes of catheter-related BSI and catheter colonisation,
while only Mimoz 1996 provided CVC-specific reports for both
outcomes per 1000 catheter-days.
The concentration of chlorhexidine-based solution used in the
studies ranged from 0.05% to 2%, with three studies using a com-
bination of chlorhexidine plus alcohol. The concentration of povi-
done-iodine was 10% in all studies except Mimoz 2007, which
used 5% povidone-iodine together with 70% ethanol. All of the
studies that evaluated alcohol used 70% isopropyl alcohol except
Dettenkofer 2010, which used a combination of 45% 2-propanol
or 74% ethanol with 10% 2-propanol.
In terms of concomitant CVC-related infection control measures,
six studies clearly described the use of maximal sterile barrier
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precaution (Dettenkofer 2010; Humar 2000; Langgartner 2004;
Mimoz 1996; Mimoz 2007; Vallés 2008), three studies described
part of the maximal sterile precaution (such as the use of sterile
gloves, gown or dressing) without explicitly mentioning maximal
sterile precaution (Levy 1988;Maki 1991; Yousefshahi 2013), and
four studies did not provide any clear description (Prager 1984;
Sadowski 1988; Tuominen 1981; Yasuda 2013).
The included studies assessed almost exclusively two major out-
comes, namely, catheter colonisation or equivalent (all 13 stud-
ies) and catheter-related BSI or equivalent (8 studies). The other
outcomes assessed were sepsis, skin colonisation, insertion site in-
fection, number of patients who required antibiotics during the
period of catheter use and adverse effects (only evaluated in one
study). Only one study reported mortality (Vallés 2008), and no
study reported cost of care or quality of life.
Control group risk of infection varied from 6.0% to 32.0% for
catheter colonisation, and from 4.1% to 9.8% for catheter-related
BSI.
Of the eight studies that evaluated the primary outcome of
catheter-related BSI, all except Yasuda 2013 clearly defined this
outcome in line with our definitions, detailed in Appendix 2. The
exact wording varied among the studies, but the definitions in-
volved a positive blood culture in the presence of catheter with
clinical evidence of sepsis, improvement of the clinical signs fol-
lowing removal of the catheters or both. One study (Yousefshahi
2013) used theCenters forDiseaseControl andPrevention (CDC)
definitions of catheter-related BSI (CDC 2011), which were
also consistent with the definitions adopted in this review. Most
studies used previously validated laboratory methods to perform
catheter and blood cultures, adopting microbiological definitions
for colonisation and bloodstream infection that were consistent
with published literature in the evaluationof catheter-related infec-
tions, including the use of molecular subtyping. In Yasuda 2013,
the published abstract did not contain the definition of catheter-
related BSI.
All studies reported catheter-related outcomes such as catheter-
related BSI and catheter colonisation using the catheter as the unit
of analysis. Ten of the 13 included studies provided the number of
participants alongside the number of catheters, althoughnone pro-
vided separate reports of the catheter-related outcomes using par-
ticipants as the unit of analysis. The number of catheters matched
the number of participants in six studies (Dettenkofer 2010;
Levy 1988;Humar 2000;Maki 1991; Sadowski 1988; Yousefshahi
2013); in three studies, the number of catheters exceeded the num-
ber of participants: by 10% in Prager 1984, 18% in Langgartner
2004 and 50% in Vallés 2008. In Tuominen 1981, there were
fewer catheters analysed than participants enrolled, with no reason
provided.
We did not incorporate the outcome data of Yasuda 2013 into
our meta-analysis, as it was published only as an abstract and did
not state the base solution used (either aqueous or alcohol) for the
povidone-iodine group.We are awaiting further information from
the authors.
In terms of funding source, one study (Dettenkofer 2010) received
funding fromanational research agency, five studies (Humar 2000;
Maki 1991;Mimoz 1996;Mimoz 2007; Prager 1984)were funded
in whole or in part by a pharmaceutical company, and in the
remaining seven studies (Langgartner 2004; Levy 1988; Sadowski
1988; Tuominen 1981; Vallés 2008; Yasuda 2013; Yousefshahi
2013), the sources of funding were not stated.
Excluded studies
We excluded a total of 83 articles based on one or more of the
following reasons.
1. Study design or article type (54 studies): the studies were
either retrospective or prospective cohort studies, cross-over
study, before-and-after intervention studies, prospective non-
randomised intervention studies, meta-analyses, economic
analyses with no original trial data, in vitro experiments, studies
with research questions or outcomes that did not match our
review, commentaries or an abstract of an included study,
excluded study or a study awaiting classification.
2. Population (17 studies): the participants in the studies were
either neonates, people undergoing haemodialysis or all patients
in ICU, not only those with CVCs in place.
3. Intervention (25 studies): the studies either assessed
antimicrobial-impregnated dressing or cerebral ventricular
catheter.
4. Insufficient information (four studies): the studies either
reported combined outcome data for arterial, venous or Swan
Gantz catheters (or a combination of these), with no separate
reporting for venous catheter and little possibility of contacting
the authors for further information, or they reported outcome
data that were unsuitable for meta-analysis.
Among the excluded articles, three articles were merged with other
articles as their secondary references on the basis of duplication
of information as stated under reason number 1 above, including
two included studies (Maki 1991;Mimoz 1996) and one excluded
study (Garland 2009b).
A description of each study is available in the ’Characteristics of
excluded studies’ table.
Risk of bias in included studies
There was a wide variation in the risk of bias of the included
studies. Overall, there was approximately a one-third split in the
domains that were judged to be low risk, unclear risk and high risk.
There was at least one high-risk domain in each of the included
studies. All studies were judged to be at high risk for blinding of
participants, except Dettenkofer 2010 (low risk) and Yousefshahi
2013 (unclear risk). Yasuda 2013 had unclear risks of bias in all
domains, as there was insufficient information in the published
abstract. The proportions of included studies with low, high and
unclear risks of bias in each domain is illustrated in Figure 2, and
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the risk of bias judgment of each included study in each domain
is depicted in Figure 3. Additionally, we have provided a detailed
descriptionof the risk of bias of each study in the ’Characteristics of
included studies’ table. We summarise our risk of bias assessments
for each domain below.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
For random sequence generation, we judged 6 of the 13 in-
cluded studies to have low risk of bias (Dettenkofer 2010; Humar
2000; Mimoz 1996; Mimoz 2007; Tuominen 1981; Vallés 2008).
For allocation concealment, three studies had low risk of bias
(Dettenkofer 2010; Langgartner 2004; Mimoz 2007). In these
studies, the authors clearly stated the method of sequence gen-
eration, which involved some form of random number scheme,
mostly by computers. There were also clear statements in the
’Methods’ that reassured the readers of the independence between
sequence generation and allocation. Two studies were judged to
be at high risk in sequence generation as well as allocation con-
cealment, as they allocated participants either using an alternate
sequence or based on their hospital registration numbers (Prager
1984; Yousefshahi 2013). There was an unclear risk of bias in one
or both domains for 8 of the 13 included studies due to insuffi-
cient information provided in the articles.
Blinding
All of the studies except Dettenkofer 2010, Yasuda 2013 and
Yousefshahi 2013 had a high risk of bias with regard to blinding of
participants. Maki 1991, Mimoz 1996 and Mimoz 2007 clearly
stated that they did not blind participants, while other studies
did not specify. However, blinding was considered very unlikely
in these studies because they compared either a skin antisepsis
regimen against no regimen, one skin antisepsis solution against
another with a different appearance, or a skin antisepsis regimen
against a different and clearly distinguishable infection control
measure with no documented attempt to mask the participants.
Eight studies did not report blinding of outcome assessors (Humar
2000; Langgartner 2004; Levy 1988; Prager 1984; Sadowski 1988;
Tuominen 1981; Yasuda 2013; Yousefshahi 2013), while the other
five did not make any clear statements one way or the other (
Dettenkofer 2010;Maki 1991;Mimoz 1996;Mimoz 2007; Vallés
2008). Although investigators objectively measured the outcome
of catheter colonisation, catheter-related BSI required some degree
of clinical judgment, which might have been affected by lack of
blinding.
Incomplete outcome data
We judged studies to have a high risk of attrition bias for the
following three reasons, alone or in combination:
1. High absolute attrition rates (≥ 20% attrition) or an
attrition rate that was higher than the event rates in the control
group
2. Vulnerability of the pooled estimates to best- and worst-
case scenarios using the dropouts in the assigned groups
3. Marked imbalance in the attrition rates between the
assigned groups.
Four studies had high risk of bias in this domain either because
they had more than 20% withdrawals (Dettenkofer 2010; Humar
2000; Langgartner 2004) or because their results changed signifi-
cantly with best- and worst-case scenarios (Vallés 2008). Six stud-
ies had low risk of bias (Levy 1988; Maki 1991; Mimoz 2007;
Prager 1984; Sadowski 1988; Yousefshahi 2013), and the infor-
mation on withdrawal was not sufficient in the remaining three
studies (Mimoz 1996; Tuominen 1981; Yasuda 2013).
Selective reporting
Nine studies had low risk of reporting bias (Dettenkofer 2010;
Humar 2000; Maki 1991; Mimoz 1996; Mimoz 2007; Prager
1984; Sadowski 1988; Tuominen 1981; Yousefshahi 2013), and
three studies carried a high risk (Langgartner 2004; Levy 1988;
Sadowski 1988). The three studies that were judged to have high
risk of reporting bias did not report key outcomes that would be
expected in such types of studies, such as catheter-related BSI,
clinical sepsis or mortality.
Other potential sources of bias
We screened for other potential sources of bias including extreme
baseline imbalance, block randomisation of unblinded trials, unit
of analysis issues and any evidence of fraud. As blinding was highly
unlikely in most included studies, the use of block randomisation
posed an additional risk of bias due to the possibility of disrupting
the integrity of the random sequence with educated guess on the
likely allocation of the future participants (Higgins 2011a). Two
studies (Humar 2000; Vallés 2008) were judged to have high risk
under ’other potential sources of bias’ as they used block randomi-
sation, and the authors did not state whether they used varying
block sizes in either trial.
Unit of analysis issues were a particular concern in three studies
(Langgartner 2004; Prager 1984; Vallés 2008), in which the num-
ber of catheters analysed exceeded the total number of participants.
This meant that some participants hadmultiple catheters analysed
in the study as the authors of the three studies did not limit one
catheter per participants in the analyses. The results might have
been affected as the outcomes data from multiple catheters from
the same participants were most likely not independent from each
other. A more detailed description of the risk of bias of the trials
is provided in ’Assessment of risk of bias in included studies’.
Effects of interventions
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See: Summary of findings for the main comparison
Chlorhexidine compared to povidone-iodine in reducing catheter
related infections
In this review, we assessed outcomes for a total of 3446 catheters in
our meta-analysis of 12 studies. The total number of participants
was unclear as some studies did not report this detail. Overall,
we carried out 10 comparisons, with variations related to the base
solution in comparisons 4 and 6.
• Comparison 1: povidone-iodine (in aqueous solution)
versus no skin antisepsis (Prager 1984).
• Comparison 2: chlorhexidine (in aqueous solution) versus
no skin antisepsis (Tuominen 1981).
• Comparison 3: alcohol versus no skin antisepsis (Sadowski
1988).
• Comparison 4: chlorhexidine versus povidone-iodine.
◦ Chlorhexidine in aqueous solution versus povidone-
iodine in aqueous solution (Maki 1991; Vallés 2008).
◦ Chlorhexidine in alcohol versus povidone-iodine in
aqueous solution (Humar 2000; Vallés 2008).
◦ Chlorhexidine in alcohol versus povidone-iodine in
alcohol (Mimoz 2007).
• Comparison 5: chlorhexidine (in aqueous solution) versus
alcohol (Maki 1991).
• Comparison 6: povidone-iodine versus alcohol.
◦ Povidone-iodine in aqueous solution versus alcohol
(Maki 1991).
◦ Povidone-iodine-impregnated adherent film versus
alcohol (Levy 1988).
• Comparison 7: alcohol versus octenidine in alcohol
(Dettenkofer 2010).
• Comparison 8: chlorhexidine (in alcohol) plus povidone-
iodine (in aqueous solution) versus chlorhexidine in alcohol
(Langgartner 2004).
• Comparison 9: chlorhexidine (in alcohol) plus povidone-
iodine (in aqueous solution) versus povidone-iodine (in aqueous
solution) (Langgartner 2004).
• Comparison 10: Sanosil (hydrogen peroxide and silver)
versus water as adjunct to chlorhexidine 2% aqueous bath plus
povidone-iodine 10% aqueous scrub (Yousefshahi 2013).
Below, we report on our outcomes of interest in order of the com-
parisons that examined them.
Primary outcomes
Catheter-related BSI
Comparison 1: aqueous povidone iodine versus no skin
antisepsis (1 RCT, 179 catheters)
Prager 1984 was the only study that compared povidone iodine
in aqueous solution versus with no skin antisepsis (dry dressing).
There was no clear evidence of a difference in the rate of catheter-
relatedBSI (RR0.99, 95%CI 0.37 to 2.61; 179 catheters; Analysis
1.1). The estimate is very uncertain as the comparison was un-
derpowered to detect important differences in the outcome. The
quality of evidence for this outcome was rated as very low due
to very serious risk of bias issues (random sequence generation,
allocation concealment, non-blinding of participants and unit of
analysis issue) as well as imprecision.
Comparisons 2: aqueous chlorhexidine versus no skin anti-
sepsis and comparison 3: alcohol versus no skin antisepsis
No study reported this outcome for these comparisons.
Comparison 4: chlorhexidine versus povidone-iodine (4
RCTs, 1436 catheters)
Overall, chlorhexidine (any solution) was associated with a lower
rate of catheter-related BSI than povidone-iodine (any solution)
(absolute risk reduction (ARR) of 2.30%, 95%confidence interval
(CI) 0.06% to 3.70%; risk ratio (RR) 0.64, 95% CI 0.41 to 0.99;
NNTB 44, 95% CI 27 to 1563; four studies, 1436 catheters, I2
= 0%; Analysis 4.1; Figure 4). This evidence was very low quality,
downgraded for imprecision (one level) and risks of bias (two lev-
els) in allocation concealment, blinding of participants and unit
of analysis issues under “other sources of bias”. Analyses of sub-
groups according to the base solution used showed no clear dif-
ferences between chlorhexidine and povidone-iodine in the rates
of catheter-related BSI: chlorhexidine in aqueous solution versus
povidone-iodine in aqueous solution (RR 0.64, 95% CI 0.32 to
1.28, 2 studies, 452 catheters, I2 = 15%), chlorhexidine in alcohol
versus povidone-iodine in aqueous solution (RR 0.77, 95% CI
0.39 to 1.53; 2 studies, 503 catheters, I2 = 0%), chlorhexidine in
alcohol versus povidone-iodine in alcohol (RR 0.40, 95% CI 0.13
to 1.24; 1 study, 481 catheters). The small number of trials in
each subgroup means that the comparisons were underpowered,
and the results are uncertain. We considered the evidence from
the data to be of very low overall quality (downgraded for impre-
cision (one level) and risks of bias (two levels) in allocation con-
cealment, blinding of participants and unit of analysis issues. We
have highlighted the results for these outcomes from the overall
comparison of chlorhexidine versus povidone-iodine as well as the
three subgroup comparisons in our Summary of findings for the
main comparison.
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Figure 4. Forest plot of comparison: 1 Chlorhexidine versus povidone-iodine, outcome: 1.1 Catheter-
related BSI.
For the outcome of catheter-related BSI per 1000 catheter-days,
chlorhexidine was associated with an apparent lower BSI rate com-
pared with povidone-iodine (RR 0.53, 95% CI 0.30 to 0.94; 4
studies, 1450 catheters, I2 = 0%; Analysis 4.2). Analyses of sub-
groups according to the base solution used found evidence of a
possible difference between chlorhexidine in alcohol versus povi-
done-iodine in aqueous solution (RR 0.49, 95% CI 0.25 to 0.95;
3 studies, 661 catheters, I2 = 31%), but relative effects were un-
clear for the other base solutions in comparison (chlorhexidine in
aqueous solution versus povidone-iodine in aqueous solution (RR
0.82, 95% CI 0.23 to 2.93; 1 study, 308 catheters), and chlorhex-
idine in alcohol versus povidone-iodine in alcohol (RR 0.41, 95%
CI 0.06 to 2.92; 1 study, 481 catheters). All subgroup compar-
isons were underpowered and the overall quality of evidence for
this outcome was very low due to very serious risk of bias issues
(non-blinding of participants, incomplete outcome data and unit
of analysis issues).
Comparison 5: aqueous chlorhexidine versus alcohol (1 RCT,
99 catheters)
A single small study compared chlorhexidine in aqueous solution
with alcohol (Maki 1991) and found no clear difference in the
absolute rate of catheter-related BSI between the alcohol-based
solution and the chlorhexidine-based solution (RR 0.24, 95% CI
0.02 to 2.54; 99 catheters; Analysis 5.1). The comparison was
underpowered and the quality of evidence for this outcome was
lowdue to risk of bias of the study (non-blinding) and imprecision.
Comparison 6: aqueous povidone-iodine versus alcohol (1
RCT, 109 catheters)
Maki 1991, the only study that compared povidone-iodine in
aqueous solution with alcohol did not find a clear difference in the
rate of catheter-relatedBSI between the twogroups (RR1.04, 95%
CI 0.24 to 5.08; 109 catheters; Analysis 6.1). The comparison was
underpowered and the quality of evidence for this outcome was
low due to risk of bias issue (non-blinding of the participants) and
imprecision.
Comparison 7: alcohol versus octenidine in alcohol (1 RCT,
387 catheters)
Dettenkofer 2010 was the only study to compare alcohol ver-
sus octenidine in alcohol, and found no clear difference between
groups in the absolute rate of catheter-related BSI (RR 2.01, 95%
CI 0.88 to 4.59; 387 catheters; Analysis 7.1) or catheter-related
BSI per 1000 catheter-days (RR 2.18, 95% CI 0.54 to 8.77; 387
catheters; Analysis 7.2). The comparison was underpowered and
the quality of evidence for both outcomes was low due to risk of
bias issue (incomplete outcome data) and imprecision.
Septicaemia (whether or not CVC-related)
Comparison 2: chlorhexidine versus no skin antisepsis (1 RCT,
136 participants)
The only study that reported the outcome of septicaemia (irre-
spective of its relationship with CVC) was Tuominen 1981, which
compared chlorhexidine with no skin antisepsis. This study of 136
participants compared the use of 0.05% chlorhexidine in aqueous
solution with no skin antisepsis and found no clear difference in
the rate of septicaemia between the two groups, but the result was
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inconclusive due to imprecision (RR 2.91, 95% CI 0.31 to 27.31;
Analysis 2.1). The quality of evidence for this outcome was low
due to risk of bias issue (non-blinding of participants) and impre-
cision, as stated above.
Mortality (all-cause or CVC-related)
Comparison 4: chlorhexidine versus povidone-iodine (1 RCT,
329 participants analysed, 106 participants in povidone-io-
dine group were included in both subgroup comparisons be-
low)
A single study (Vallés 2008) reported mortality. The study divided
the participants into three groups: chlorhexidine in aqueous so-
lution, chlorhexidine in alcohol and povidone-iodine in aqueous
solution. Analyses according to subgroups showed no clear dif-
ferences in the rates of mortality between chlorhexidine in aque-
ous solution and povidone-iodine in aqueous solution (RR 1.15,
95% CI 0.72 to 1.83; 213 participants) (Analysis 4.3), or between
chlorhexidine in alcohol and povidone-iodine in aqueous solu-
tion (RR 0.80, 95% CI 0.48 to 1.34; 222 participants) (Analysis
4.3)(Figure 5). However, the comparison was underpowered to
detect important differences in the outcome, and the quality of
evidence for both analyses was low due to a combination of risk of
bias issues and imprecision in the outcome estimates (Summary of
findings for the main comparison). Consequently true differences
in the mortality associated with use of chlorhexidine or povidone
iodine cannot be ruled out.
Figure 5. Forest plot of comparison: 1 Chlorhexidine versus povidone-iodine, outcome: 1.3 All-cause
mortality.
Secondary outcomes
Catheter colonisation
Comparison 1: aqueous povidone-iodine versus no skin
antisepsis (1 RCT, 179 catheters)
Based on Prager 1984, the only study in this underpowered com-
parison, it is unclear whether there is any difference in the effect
on catheter colonisation of aqueous povidone iodine and no skin
antisepsis (RR 0.93, 95% CI 0.53 to 1.60; 179 catheters; Analysis
1.2). There was very low quality evidence due to serious risk of
bias (random sequence generation, allocation concealment, non-
blinding of participants and unit of analysis issue) and indirectness
of the outcome.
Comparison 2: aqueous chlorhexidine versus no skin
antisepsis (1 RCT, 124 catheters)
Based on Tuominen 1981, the only study to compare chlorhex-
idine in aqueous solution with no skin antisepsis, there was no
clear difference in the rate of catheter colonisation and therefore
uncertainty as to their relative effects remains (RR 1.26, 95% CI
0.61 to 2.59; 124 catheters; Analysis 2.2). The quality of evidence
was very low due to risk of bias (non-blinding of participants),
indirectness of the outcome and imprecise estimate from an un-
derpowered analysis.
Comparison 3: alcohol versus no skin antisepsis (1 RCT, 50
catheters)
Based on a single study in this underpowered analysis (Sadowski
1988), it remains unclear whether there is a difference between
cleansing the skin with alcohol and no skin antisepsis prior to
catheter removal (RR 0.75, 95% CI 0.30 to 1.85; 50 catheters;
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Analysis 3.1). The quality of evidence was very low due to risk of
bias (non-blinding of the participants), indirectness and impreci-
sion.
Comparison 4: chlorhexidine versus povidone-iodine (5
RCTs, 1533 catheters)
Pooled analysis of five studies that compared chlorhexidine with
povidone iodine showed an overall reduction in the risk of catheter
colonisation with chlorhexidine (RR 0.68, 95% CI 0.56 to 0.84;
ARR 8%, 95% CI 3 to 12%; NNTB 13, 95% CI 9 to 34; 5 stud-
ies, 1533 catheters, I2 = 55%; Analysis 4.4; Figure 6). Analysing
subgroups according to the solution, there appeared to be reduc-
tions in rates of catheter colonisation favouring chlorhexidine in
the following comparisons:
Figure 6. Forest plot of comparison: 1 Chlorhexidine versus povidone-iodine, outcome: 1.4 Catheter
colonisation.
• Chlorhexidine in aqueous solution versus povidone-iodine
in aqueous solution (RR 0.60, 95% CI 0.40 to 0.91; 2 studies,
442 catheters, I2 = 56%).
• Chlorhexidine in alcohol versus povidone-iodine in alcohol
(RR 0.52, 95% CI 0.34 to 0.80; 1 study, 481 catheters).
However, the rate of catheter colonisation between chlorhexidine
in alcohol versus povidone-iodine in aqueous solution appeared to
be similar (RR0.86, 95%CI 0.64 to 1.14; 3 studies, 600 catheters,
I2 = 58%).
There was moderate heterogeneity present for the overall pooled
analysis, as indicated by the I2 of 55%. The extent of heterogeneity
remained evenwith the studies separated into subgroups according
to the solution used, as shown above. We investigated other possi-
ble sources of heterogeneity by exploring factors that were present
in the population, intervention, comparison, outcome definitions
and risk of bias among the included studies. We noted that al-
though there were some differences in the characteristics of the
included studies in terms of population (surgical versus cardiac
versus general ICUs) and intervention (different concentrations of
chlorhexidine used, duration of catheterisation and the concurrent
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use of other antiseptic substances alongside chlorhexidine-based
solution), these differences did not plausibly explain the degree of
heterogeneity, as separating the studies into subgroups according
to these factors did not reduce the degree of heterogeneity.
However, we identified one plausible source of heterogeneity un-
der the risk of bias criterion.We found that only two out of five in-
cluded studies (Maki 1991;Mimoz 1996) had low risk of attrition
bias, while the other three were at high risk of bias in this domain.
The two studies with low risk of attrition bias showed significant
benefits of chlorhexidine compared with povidone-iodine, whilst
the remaining studies showed no significant difference between
the two groups. Grouping studies with low risk and high risk of
attrition bias separately reduced the I2 statistic to 0% and 41%,
respectively.
We undertook best- and worst-case scenarios to determine the im-
pact of missing data from these three studies and found that the
overall pooled analysis was substantially altered, with the best-case
scenario moving the direction of the pooled estimate to signifi-
cantly and substantially favour the chlorhexidine group, and the
worst-case scenario moving the pooled estimate to significantly
favour the povidone-iodine group (see ’Sensitivity analysis’ for de-
tails).
Having identified a plausible explanation for the observed hetero-
geneity, we still decided to combine all five studies under three
different subgroups according to the type of solution used (either
aqueous or alcohol). Taking all considerations, the overall quality
of evidence for this outcome was very low, as there were very seri-
ous concerns regarding risk of bias (non-blinding of participants,
incomplete outcome data and unit of analysis issue), indirectness
of the outcome and inconsistency among the study results.
Comparison 5: aqueous chlorhexidine versus alcohol (1 RCT,
99 catheters)
According to a single study (Maki 1991), it remains unclear
whether there is a difference in the rates of catheter colonisation
between chlorhexidine in aqueous solution and alcohol (RR 0.38,
95% CI 0.11 to 1.33; 99 catheters; Analysis 5.2), but the compar-
ison was underpowered. The quality of evidence for this outcome
was very low due to risk of bias (non-blinding of participants),
indirectness and imprecision.
Comparison 6: aqueous povidone-iodine versus alcohol (3
RCTs, 169 catheters)
It is unclear whether there is a difference in the rates of catheter
colonisation between patients who received CVC cleansing with
povidone-iodine and those who receive cleansing with alcohol,
either overall (RR 1.76, 95% CI 0.76 to 4.09; 2 studies, 169
catheters, I2 = 43%), or in subgroups comparing povidone-iodine
in aqueous solution versus alcohol (RR1.25, 95%CI 0.49 to 3.14;
1 study, 109 catheters) or povidone-iodine-impregnated adherent
film versus alcohol (RR 9.00, 95% CI 0.51 to 160.17; 1 study,
60 catheters; Analysis 6.2). The comparisons were underpowered,
and the overall quality of evidence for this outcome was very low
due to risk of bias (non-blinding of participants), indirectness of
the outcome and imprecision.
Comparison 7: alcohol versus octenidine in alcohol (1 RCT,
322 catheters)
Dettenkofer 2010, the only study to compare alcohol versus
octenidine in alcohol, showed that alcohol alone is probably as-
sociated with a higher rate of catheter colonisation compared to
octenidine (RR2.26, 95%CI 1.22 to 4.21; 322 catheters; Analysis
7.3). However, there appeared to be no clear difference between
the two groups in terms of catheter colonisation per 1000 catheter-
days (RR 2.23, 95% CI 0.79 to 6.29; 322 catheters; Analysis 7.4).
The quality of evidence for both outcomes was low, due to con-
cerns in risk of bias (non-blinding of participants) and indirectness
of the outcomes.
Comparison 8: chlorhexidine in alcohol plus povidone-
iodine in aqueous solution versus chlorhexidine in alcohol (1
RCT, 88 catheters)
In an underpowered analysis from a single study (Langgartner
2004), a combination of chlorhexidine plus povidone-iodine ap-
peared to be associated with lower rate of catheter colonisation
(RR 0.19, 95% CI 0.04 to 0.81; 88 catheters; Analysis 8.1) as well
as catheter colonisation per 1000 catheter-days (RR 0.19, 95%CI
0.06 to 0.59; 88 catheters; Analysis 8.2) compared with chlorhex-
idine alone, although the effects were uncertain due to the very
low quality of evidence, which was reduced by risk of bias (non-
blinding of participants, incomplete outcome data, unit of analy-
sis issue), indirectness and imprecision.
Comparison 9: chlorhexidine in alcohol plus povidone-
iodine in aqueous solution versus povidone-iodine in
aqueous solution (1 RCT, 95 catheters)
In another single-study, underpowered analysis based on
Langgartner 2004, there appeared to be lower rate of catheter
colonisation (RR0.15, 95%CI0.04 to 0.62; 95 catheters; Analysis
9.1) as well as catheter colonisation per 1000 catheter-days (RR
0.17, 95%CI0.05 to 0.52; 95 catheters; Analysis 9.2) using a com-
bination of chlorhexidine and povidone-iodine compared with us-
ing povidone-iodine alone, but the effects were very uncertain due
to the very low quality of evidence, which was reduced by risk of
bias (non-blinding of participants, incomplete outcome data, unit
of analysis issue), indirectness and imprecision.
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Comparison 10: Sanosil (hydrogen peroxide and silver)
versus water as adjunct to chlorhexidine 2% aqueous bath
plus povidone-iodine 10% aqueous scrub (1 RCT, 249
catheters)
From the single study in this underpowered comparison (
Yousefshahi 2013), it is uncertain whether there is any clear differ-
ence between the two groups in the rate of catheter colonisation
(RR 1.08, 95% CI 0.68 to 1.72; 249 catheters; Analysis 10.1) due
to the very low quality of evidence, which was reduced by risk of
bias (random sequence generation, allocation concealment), indi-
rectness and imprecision.
Insertion site infection
Comparison 4: Chlorhexidine versus povidone-iodine (1
RCT, 242 catheters)
Based on the result of a single study (Humar 2000) in an under-
powered analysis, it is uncertain whether there is any clear differ-
ence between chlorhexidine (in alcohol) and povidone-iodine (in
aqueous solution) with regard to insertion site infection, as the
quality of evidence was very low due to risk of bias (non-blind-
ing of the participants, incomplete outcome data), indirectness
and imprecision. The authors reported this outcome as the mean
CFU count (MD− 2.80, 95% CI − 9.10 to 3.50; 242 catheters;
Analysis 4.6).
Skin colonisation
Comparison 7: Alcohol versus octenidine in alcohol (1 RCT,
365 catheters)
Based on the results of Dettenkofer 2010, using alcohol alone
probably resulted in higher mean CFU compared with octeni-
dine in alcohol (MD 79.00 CFUs, 95% CI 32.76 to 125.24; 365
catheters; Analysis 7.5). The quality of evidence was moderate as
it was reduced by imprecision of the effect estimates from an un-
derpowered analysis.
Adverse effects
Comparison 7: Alcohol versus octenidine in alcohol (1 RCT,
398 participants)
A single study, Dettenkofer 2010, reported the rates of various ad-
verse effects on the skin, the definitions of which appeared to over-
lap. For example, the authors reported “skin irritation”, “burning”,
“skin irritation and burning”, “itching”, “skin lesions”, “burning
and skin lesions”, “itching and skin irritation” as the outcomes
under adverse effects. To avoid duplication, we included only the
most commonly reported adverse effect, namely, skin irritation.
For this outcome, there was moderate quality evidence showing
no clear difference between in adverse effect rates between patients
whose CVC sites were cleansed with alcohol and those who were
cleansed with octenidine in alcohol (RR 0.85, 95% CI 0.60 to
1.20; 398 participants; Analysis 7.6). The quality of evidence was
reduced by imprecision of the effect estimates from an underpow-
ered analysis.
Number of patients who were on antibiotics during the
period of catheter use
Comparison 2: Chlorhexidine in aqueous solution versus no
skin antisepsis ( 1 RCT, 136 participants)
The only study that evaluated this outcome, Tuominen 1981
found no clear difference between the two groups with regard to
the number of patients who required antibiotics during the period
of catheter use (RR 0.84, 95% CI 0.55 to 1.27; 136 participants;
Analysis 2.3). The quality of evidence was low due to risk of bias
(non-blinding of participants) and imprecision from an under-
powered analysis.
Number of drug-resistant organisms from culture, length of
hospitalisation, cost of care and quality of life
No studies in any comparison assessed these outcomes.
Subgroup analyses
Other than separating the subgroups according to the type of
solution used in comparisons 4 and 6, we did not perform any
additional subgroup analyses as specified in our ’Methods’ because
the data in each study were not presented separately for various
potential subgroups (for short term versus longer term CVCs, for
paediatric versus adult patients and for patients in ICUversus those
in other wards). Likewise, there was only a single study included
in many comparisons, and all studies in the meta-analysis used
diagnostic criteria for catheter-related infections that were in line
with our pre-specified criteria (see ’Included studies’).
Sensitivity analysis
We performed sensitivity analyses on themost commonly assessed
outcomes, namely, catheter-related BSI (primary outcome) and
catheter colonisation (secondary outcome) to evaluate the impact
of excluding some studies based our predefined criteria (unclear or
no allocation concealment (selection bias) and significant dropout
rates (attrition bias)). We assessed the impact of missing data in
studies with high dropout rates using the best- and worst-case
scenarios. We did not carry out a sensitivity analysis according to
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the criterion of blinding because we considered that all but one
study were at high risk in this domain.
Catheter-related BSI
Comparison 4: Chlorhexidine versus povidone-iodine
Selection bias: None of the four studies included were at low
risk of bias for both random sequence generation and allocation
concealment. Maki 1991 was at unclear risk for both items while
the other three studies were at low risk for at least one of the
items. We decided to perform the sensitivity analysis by excluding
Maki 1991. While the point estimate changed only slightly, the
confidence interval expanded to cross the line of no effect, shifting
the result to become non-significant (before exclusion: RR 0.64,
95% CI 0.41 to 0.99; after exclusion: RR 0.68, 95% CI 0.43 to
1.08).
Attrition bias: Two studies had a high risk of attrition bias (Humar
2000, Vallés 2008). We conducted best- and worst-case scenarios
by assuming the outcome for the patients with missing data as
described in the Dealing with missing data section. The direction
of the pooled estimate differed markedly between the best- and
worst-case scenarios as well as from the actual results reported,
namely the ’completer analysis’ (best-case scenario: RR 0.35, 95%
CI 0.24 to 0.50, I2: 0%; worst-case scenario: RR 1.47, 95% CI
1.01 to 2.14, I2: 64%; actual results reported: RR 0.64, 95% CI
0.41 to 0.99, I2: 0%).
There was only a single study included for all the other compar-
isons.
Catheter colonisation
Comparison 4: Chlorhexidine versus povidone-iodine
Selection bias: One study (Maki 1991) had unclear risk of bias
in both random sequence generation and allocation concealment,
whilst the other studies were at low risk of bias for at least one
item. The exclusion of Maki 1991 did not result in a substantial
change in the pooled estimates (before exclusion: RR 0.68, 95%
CI 0.56 to 0.84; after exclusion: RR 0.72, 95% CI 0.58 to 0.88).
Attrition bias: Three of the five studies (Humar 2000;
Langgartner 2004; Vallés 2008) included in this comparison had
high or unclear risk of attrition bias. We conducted best- and
worst-case scenarios. With the best-case scenario, the pooled esti-
mate showed substantial reduction in the risk of catheter coloni-
sation favouring the chlorhexidine group (RR 0.56, 95% CI 0.47
to 0.68, I2: 73%), and with the worst-case scenario, there was no
significant difference between the two groups (RR 0.90, 95% CI
0.74 to 1.09, I2: 72%). Results from both the best- and worst-
case scenarios differed markedly with the actual results reported,
namely the ’completer analysis’ (RR 0.68, 95% CI 0.56 to 0.84,
I2: 55%).
There were insufficient studies in all the other comparisons to
enable a meaningful sensitivity analysis.
D I S C U S S I O N
Summary of main results
This review identified a wide variety of skin antisepsis regimens
that comprised different combinations of an active substance (such
as chlorhexidine) and base solution (such as aqueous or alcoholic
solution). However, a limited number of studies (and sometimes
just one) examined each regimen. Based on very limited evidence,
there were no clear differences between various skin antisepsis reg-
imens for our primary outcome of catheter-related BSI, although
for the overall comparison between chlorhexidine and povidone-
iodine, there appeared to be a reduction in catheter-related BSI
associated with chlorhexidine. Notably, two studies conducted in
the 1980s, one comparing povidone-iodine in aqueous solution
with no skin antisepsis and the other comparing chlorhexidine in
aqueous solution with no skin antisepsis, found no difference in
the rates of BSI between the intervention group and the control
group (Prager 1984; Tuominen 1981). However, these were small
studies with some methodological issues, and the evidence they
provide is very inconclusive.
Based on a single study (Vallés 2008), there were similar rates
of mortality between chlorhexidine-based solution and povidone-
iodine based solution. However, the analyses were underpowered
for any clear conclusion to be drawn with regards to this outcome.
In the outcome of catheter colonisation, some differences existed
between different skin antisepsis regimens, with regimens contain-
ing chlorhexidine appearing to be more effective than regimens
containing povidone-iodine in reducing risk.
One trial showed that octenidine in alcohol appeared to bemore ef-
fective than alcohol alone in reducing catheter colonisation. Three
separate studies that compared chlorhexidine, povidone-iodine
and alcohol-based solution, respectively, with no skin antisepsis
did not find any clear difference in the rates of catheter coloni-
sation between the intervention group and the control group, al-
though the amount of evidence based on these studies is insuffi-
cient to draw any clear conclusion. Analysis based on very small
number of studies and catheters suggested that a combination of
chlorhexidine and povidone-iodine appeared to be more effective
than either agent alone in reducing catheter colonisation. Single-
study analyses showed that there were no clear differences in the
rates of insertion site infection, skin colonisation or adverse events
between different skin antisepsis regimens examined. Overall, the
results of this meta-analysis need to be interpreted with caution, as
the majority of the included studies were not sufficiently powered
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to detect a clear difference in the outcomes, and some significant
results came from small, methodologically flawed studies, as men-
tioned above.
Overall completeness and applicability of
evidence
We identified 13 studies that matched our selection criteria in
terms of population, intervention, comparison and outcomes, and
data were unavailable for analysis in 1 out of 13 studies. A total
of 3446 catheters were assessed. The studies took place in Europe,
the USA and Asia, from 1981 to 2013, in settings where CVCs are
commonly used, such as the ICUs and haematology and oncology
units. However, there are certain limitations in the completeness
of this review. For example, among the participants, children were
grossly underrepresented, and most of the included studies did
not adequately asses some of the key prespecified outcomes of this
review, includingprimaryBSIs,mortality, adverse effects and costs.
Furthermore, we were unable to undertake most of the subgroup
analyses because there were insufficient data.
Quality of the evidence
Overall, the quality the evidence for the majority of outcomes
assessed was very low to moderate due to the small number of
studies included in each comparison and variable risk of bias of the
included studies. The strongest evidence comes from the overall
comparison between antiseptic solutions containing chlorhexidine
against antiseptic solutions containing povidone-iodine, for which
there were five studies. However, all comparisons in this review
suffered from a lack of power in the analysis, as evidenced by the
small number of trials and catheters in each comparison. The lack
of power in the analysis has seriously affected our confidence in
interpreting the results in general, as we were unable to determine
whether non-statistically significant results were indicative of true
(null) effects or of insufficient data for detecting differences. Also,
in the case of a statistically significant difference, an analysis with
a small number of trials and catheters lessens the reliability of
the results due to concerns about the effects of small studies in
exacerbating the impact of biases (Sterne 2011).
A second major limitation in the quality of the evidence gathered
was the risk of attrition bias, as four studies had high risks and three
had unclear risks. In studies with high risk of attrition bias, the
pooled results varied substantially between the best- andworst-case
scenarios and from the actual results reported, and this precluded
us from drawing a firm conclusion on the results of the outcomes
concerned. Besides, a lack of blinding of the participants in most
studies, as well as the unit of analysis issues in some studies in
which multiple catheters in the same participants were analysed
as separate units has further affected the overall methodological
rigour of the included studies, and in turn the quality of evidence.
Overall, the body of evidence gathered in this review did not allow
us to reach a robust conclusion regarding the effectiveness and
safety of various skin antisepsis regimes in reducing CVC-related
infections (see Summary of findings for the main comparison for
the outcome data under the major comparisons in this review).
Potential biases in the review process
We performed a comprehensive search of multiple databases with
independent screening, selection and assessment of eligible studies.
However, wewere unable to obtain all relevant data; five studies are
awaiting assessment, as there were difficulties obtaining full texts,
and another one is an ongoing study.Many of the excluded studies
assessed a combination of arterial and venous catheters but did
not report outcome data separately for CVC, which prevented us
from including a larger body of potentially relevant information.
We are currently waiting for authors of the studies concerned to
provide us relevant data for our future updates.
There are some unresolved unit of analysis issues in this review:
for catheter-specific outcomes such as catheter-related BSI and
catheter colonisation, we reported the results in the same way as
the original studies, using catheters rather than participants as the
unit of analysis. As a result, the review included multiple catheters
in the same participants. Our failure to adjust for this unit of
analysis issue might have affected the results.
Agreements and disagreements with other
studies or reviews
The findings of this review are broadly in line with two other re-
views on this topic (Adams 2007; Chaiyakunapruk 2002), which
concluded that antiseptic solutions containing chlorhexidine are
more effective than those containing povidone-iodine in reducing
catheter colonisation and catheter-related BSI. Of the two reviews,
Adams 2007was a narrative review andChaiyakunapruk 2002 was
a systematic review that evaluated chlorhexidine against povidone-
iodine in all vascular catheters, including arterial and central and
peripheral venous catheters. Chaiyakunapruk 2002 showed that
antiseptic solutions containing chlorhexidine reduced catheter-re-
lated BSI on average by 49% compared with povidone-iodine,
although there was a great degree of uncertainty on the magni-
tude of its benefit, as reflected by a wide confidence interval (RR
0.51, CI 0.27 to 0.97; 8 RCTs including three that evaluated only
CVCs, 4143 arterial and venous catheters combined including
1493 CVCs). Our review, which is focused only on central venous
catheters, included two more trials but a slightly smaller number
of CVCs, and we showed that a solution containing chlorhexidine
reduced catheter-related BSI by an average of 36% (relative ef-
fect) compared with povidone-iodine (RR 0.64, CI 0.41 to 0.99;
5 studies, 1436 CVCs).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Very low quality evidence suggests that antiseptic solutions
containing chlorhexidine may reduce catheter colonisation and
catheter-related BSI compared with antiseptic solutions contain-
ing povidone-iodine. It is unclear whether skin cleansing for CVCs
with any solution is beneficial compared with no skin antisepsis. It
is still unclear whether skin antisepsis as part of CVC care reduces
overall sepsis and mortality. While the evidence gathered in this
review does not change the current recommendations that favour
the use of chlorhexidine-containing solution for skin antisepsis in
CVC care, uncertainties remain on its value in improving patient
mortality and morbidity.
Implications for research
Further trials in skin antisepsis in patients with a CVC are war-
ranted. This review highlights the paucity of high-quality research
answering questions on whether skin antisepsis in patients with
CVC reduces overall rates of sepsis and mortality. Furthermore,
the evolving patterns of hospital-associated infections, accompa-
nying progress in infection control measures and microbiologi-
cal diagnostic techniques have resulted in changing effectiveness
of various interventions employed. Future trials should include
the two key outcomes, overall rate of sepsis and mortality, along-
side catheter-specific outcomes such as catheter-related BSI and
catheter colonisation, with a clear description of the settings, par-
ticipants and concurrent infection control measures to enable an
evaluation of the results in relation to these factors. If possible,
investigators should blind participants and personnel, or at the
very least outcome assessors, with measures in place (such as train-
ing of care personnel on handling the catheters for the purpose
of research and the implementation of a standard protocol with
regards to the handling of study catheters during and after office
hours) to reduce loss of data.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dettenkofer 2010
Methods Multicentre RCT (Switzerland)
Study period: May 2002 to June 2005
Setting: 2 haematology units and 1 surgical unit in 2 university hospitals
Participants Adult patients who required a CVC.
Number of participants: 400
Number of catheters; 400
Age: median age of 59 years (25% quartile of 48 to 70 years)
Sex: 66% male overall
Interventions 2-arm comparison of skin antisepsis prior to catheter insertion
1. Intervention A: 0.1% octenidine with 30% I-propanol plus 45% 2-propanol.
2. Intervention B: 74% ethanol with 10% 2-propanol.
Outcomes • Catheter colonisation
• Skin colonisation
• Catheter-related BSI
• Adverse events
Outcomes assessed at various points during in-patient stay.
Notes The unit of analysis was patient, and it appeared that 1 catheter per patient was analysed
although this was not stated explicitly
Funding source: the study was funded partly by the Swiss National Science Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Methods’, ’Randomisation and interven-
tions’: “The randomisation code was pro-
duced by the independent Centre for Clin-
ical Studies using computerised random
number generator… used a stratification
factor and block randomisation with ran-
domly varying block length”
Allocation concealment (selection bias) Low risk ’Methods’, ’Randomisation and interven-
tions’: As above, and “The randomisation
was realised using closed envelopes, ensur-
ing that the sequence was concealed before
patients entered the trial.”
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Dettenkofer 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Methods’, ’Randomisation and interven-
tions’: “The patients, staff administering
the intervention, themicrobiology labwere
all blinded to the assignment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Methods’, ’Randomisation and interven-
tions’: “The patients, staff administering
the intervention, themicrobiology labwere
all blinded to the assignment”
Incomplete outcome data (attrition bias)
All outcomes
High risk Discussion, paragraph 2: “20% of the
catheters were not cultured, however they
were equally distributed”. The absolute
rate of post randomisation exclusion was
high for the outcome of catheter colonisa-
tion. However, the authors appeared to fol-
low the intention-to-treat principle as they
analysed the patients forwhom the datawas
available in the originally assigned group
Selective reporting (reporting bias) Low risk Authors reported all 4 major outcomes as
stated in the ’Methods’, namely, catheter
colonisation, skin colonisation, catheter-
related BSI and adverse effects in sufficient
detail in the ’Results’
Other bias Low risk None identified
Humar 2000
Methods Multicentre RCT (Canada)
Study period: Period of study not specified but authors stated that study conducted over
1 year (paragraph 1, results)
Setting: hospital-wide
Participants ’Patients and methods’, ’Patients’: “All patients > 18 years of age who had CVCs inserted
for any purpose were eligible for inclusion in the study, provided the treating physician
felt the inserted catheter would be present for a minimum of 72 hours.”
Number of participants: 242
Number of catheters; 374
Age: mean of 58.3 years +/- range of 16.8 years (chlorhexidine group ) and 62.2 years
+/- range of 16.0 years (povidone-iodine group)
Sex: 78% male in chlorhexidine group and 72% male in povidone-iodine group
Interventions Comparison of 2 active agents for initial and subsequent cutaneous antisepsis for catheter
care
1. Intervention A: 10% povidone-iodine.
2. Intervention B: 0.5% tincture of chlorhexidine.
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Outcomes assessed at various points during in-patient stay.
Outcomes • Catheter-related BSI (definite and probable)
• Catheter colonisation
• Insertion site infection
Notes Funding source: the study was funded by Physicians Services Incorporated (North York,
Ontario,
Canada) and Medi-Flex (Overland Park, KS).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Methods’, ’Study design’: Randomisation
was achieved “by the use of blinded block
randomisation schedule”
Allocation concealment (selection bias) Unclear risk Although the authors stated that the block
randomisation schedule was “blinded”,
there was no further information provided
on how treatment assignmentwas allocated
using the random sequence generated at the
time of enrolment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors did not report whether blind-
ing was achieved; blinding for clinical out-
come assessment was highly unlikely be-
cause the antiseptic solutions used differed
in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding for microbiological outcome as-
sessment was unclear as this was not stated
in the paper
Incomplete outcome data (attrition bias)
All outcomes
High risk For the outcomes of catheter-related BSI
and catheter colonisation, trialists only
analysed 180 out of 242 patients that were
initially enrolled (74%). The authors stated
that 62 catheters were not analysed because
the catheter tips were not available for cul-
ture, the underlying reasons of which were
not provided
For the outcome of insertion site (“exit
site”) infection which was not dependent
on catheter culture, trialists included all
242 patients in the analysis
The authors appeared to follow the inten-
tion-to-treat principle as they analysed the
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patients for whom the data was available in
the originally assigned group
Selective reporting (reporting bias) Low risk Authors reported all the outcomes stated in
the ’Methods’ with sufficient detail in the
’Results’
Other bias High risk The study employed a block randomisation
schedule with high likelihood that blind-
ing of participants and personnel could
not be achieved. This posed a risk to the
integrity of the random sequence which
would be vulnerable to disruption follow-
ing educated guesses by those involved in
the study on the likely assigned group of
the future participants
Langgartner 2004
Methods Single-centre RCT (Germany)
Study period: May 1999 to August 2002.
Setting: Inpatient hospital wards and ICUs
Participants ’Materials andmethods’: ”Adult inpatients scheduled for elective CVC placement during
normal working hours were eligible for participation in the study. Patients from normal
wards as well as from the intensive care units were included. Patients known to be allergic
to iodine or chlorhexidine were excluded as were all patients who needed a CVC placed
under emergency conditions. No underlying disease was defined as an exclusion criteria.
“
Number of participants: 119
Number of catheters: 200 (140 analysed)
Age: mean age ranged from 50.5 to 56.6 years (SD ranged from 14.8 to 17.2 years)
(reported separately according to three groups)
Sex: overall 60.7% male.
Interventions Skin disinfection prior to catheter insertion and daily during the change of dressings
with 1 of the 3 regimens
1. Intervention A: povidone-iodine 10% aqueous solution.
2. Intervention B: propanol 70%/chlorhexidine 0.5%.
3. Intervention C: propanol 70%/chlorhexidine 0.5% followed by PVP-iodine 10%.
Outcomes assessed at various points during in-patient stay.
Outcomes Catheter colonisation
Notes Funding source: not stated.
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk ’Materials andmethods’: ”Sealed and num-
bered envelopes contained the randomisa-
tion code together with the instructions for
skin disinfection and forms for the docu-
mentation of the procedure.“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of patients and carers not re-
ported, although blinding appeared very
unlikely because the number of antiseptic
solution used for each group and their ap-
pearances were different
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not statedwhether the personnel tak-
ing the swabs and the interpreter of the mi-
crobiological tests were blinded to the allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
High risk ’Materials and methods’: ”In addition to
the 140 catheters evaluated, 60 more
catheters had been included but had to
be excluded from analysis: in 5 cases, pa-
tients had died with the catheter in place,
in 38 cases microbiological analysis of the
catheter tip had not been performed and
17 catheters were lost during follow-up (e.
g. the patient was taken to a different clinic
with the CVC in place).”
In total, 200 catheters were recruited but
only 140were evaluated,which represented
an overall dropout rate of 30%. It was un-
clear why trialists did not performmicrobi-
ological analyses in the 38 catheters asmen-
tioned
However, the authors appeared to fol-
low the intention-to-treat principle as they
analysed the patients forwhom the datawas
available in the originally assigned group
Selective reporting (reporting bias) High risk The only outcome stated in the ’Meth-
ods’ and reported was catheter coloni-
sation. Some important outcomes such
as catheter-related blood stream infection,
clinical sepsis and mortality were not re-
ported
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Other bias High risk There was a unit of analysis issue in
which the number of catheters analysed
exceeded the number of participants by
nearly 18%, and the outcome was reported
using catheters as the units
Levy 1988
Methods Single-centre RCT (USA)
Study period: not reported
Setting: no clear description of the study setting except that the study was conducted on
“patients undergoing coronary artery surgery”
Participants ’Patients and methods’: “60 patients scheduled for coronary artery surgery were studied
during right internal jugular vein cannulation for PA catheter insertion.”
Number of participants: 60
Number of catheters;60
Age: not reported
Sex: not reported
Interventions Comparison of 2 skin preparation regimes before insertion of CVC
1. Intervention A: 1 minute-cleaning with 70% isopropyl alcohol followed by
draping with a sterile non-absorbent sheet with an iodophor-impregnated adherent
film placed over the aperture.
2. Intervention B: povidone-iodine swabs followed by draping with a sterile non-
absorbent sheet.
Outcomes • Catheter colonisation
• Bacterial contamination of surgical gloves
Outcomes assessed at various points during in-patient stay.
Notes Funding source: not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Patients and methods’: “Patients were as-
signed randomly assigned to one of two
groups.”
There was no further information, includ-
ing on random sequence generation
Allocation concealment (selection bias) Unclear risk There was no information in the paper to
enable an assessment on whether random
sequence generationwas independent from
allocation
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Although the authors did not explicitly say,
blinding of the patient and personnel was
highly unlikely because the 2 skin antisep-
sis regimes differed in the way of admin-
istration (1 using a liquid solution and an
additional adherent film and the other us-
ing a swab without an adherent film)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding for microbiological outcome as-
sessment not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Authors analysed all 60 participants ini-
tially enrolled and seemed to follow the in-
tention-to-treat principle
Selective reporting (reporting bias) High risk Authors reported both major outcomes
named in the ’Methods’, catheter coloni-
sation and positive glove culture, in suffi-
cient detail in the ’Results’. However, they
did not include major patient-related out-
comes such as catheter-related BSI, sepsis
or mortality
Other bias Low risk None identified
Maki 1991
Methods Single-centre RCT (USA)
Study period: 1986-1987.
Setting: surgical ICU
Participants All adult patients over 18 years old
Number of participants:176
Number of catheters;176
Age: mean age ranged from 51 to 53 years (SD of 19 in all three groups)
Sex: not reported.
Interventions Skin antisepsis prior to CVC insertion and every 48 h thereafter using 1 of 3 antiseptic
solutions
1. Intervention A: 10% povidone-iodine.
2. Intervention B: 70% isopropyl alcohol.
3. Intervention C: 2% chlorhexidine gluconate.
Outcomes • “Catheter-related infections” (catheter colonisation)
• “Catheter-related bacteraemia” (catheter-related BSI)
Outcomes assessed at various points during in-patient stay.
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Notes Although not clearly stated, it appeared that each patient had only 1 catheter included
in the study, as Table 1 in the article suggested. Authors studied both venous and arterial
catheters and reported outcome data separately
Funding source: partly funded by Stuart Corporation (ICI, Ltd) of Wilmington,
Delaware
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Materials and methods’, ’Procedures for
insertion and care of catheters’: “At the time
of insertion, each catheter was randomised
to one of three antiseptic solutions . . .”
There was no description of random se-
quence generation
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ’Materials and methods’, ’Source of clinical
data’: “Although it was not possible for the
users or the research nurses to be blinded
to the antiseptic agent used . . .”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Materials and methods’, ’Source of clinical
data’: “[T]he research microbiologist who
processed all cultures had no knowledge of
the antiseptic group to which the catheter
had been assigned”
Incomplete outcome data (attrition bias)
All outcomes
Low risk It appeared that there were no with-
drawals, as the number of catheters anal-
ysed matched the number of catheters en-
rolled initially. The authors appeared to
follow the intention-to-treat principle by
analysing the catheters in the originally as-
signed groups
Selective reporting (reporting bias) Low risk Authors reported both major outcomes of
catheter colonisation and catheter-related
BSI as stated in the ’Methods’ in sufficient
detail in the ’Results’. An additional out-
come of adverse event was reported, al-
though this was reported as an overall per-
centage without separating venous from ar-
terial catheters
Other bias Low risk None identified
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Methods Single-centre RCT (France)
Study period: 1 July 1992 to 31 October 1993
Setting: surgical-trauma ICU
Participants Consecutive patients aged 18 years and above who were scheduled to receive a non-
tunnelled central venous catheter, an arterial catheter or both
Number of participants: not reported
Number of catheters; 158
Age: mean age from 51 to 54 years (SD 18 to 19)(reported separately in two groups)
Sex: not reported
Interventions Comparison of the following 2 skin antiseptic regimens prior to catheter insertion and
every 48 h post insertion
1. Intervention A: 0.25% chlorhexidine+ 0.025% benzalkonium
2. Intervention B: 10% povidone-iodine
Outcomes • Catheter colonisation
• Catheter-related BSI
Outcomes assessed at various points during in-patient stay.
Notes Trialists studied both arterial catheters and CVCs. They did not report data separately
for CVC and arterial catheters except for the outcomes of catheter colonisation per 1000
catheter-days and catheter-related sepsis per 1000 catheter-days
Funding source: funded in part by Les Laboratoires Nicholas, Gaillard, France
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Materials and methods’, ’Randomisation
procedure’: ”Each patient requiring at least
one catheter was randomly allocated to one
of two groups by drawing envelopes from
an urn.“
Allocation concealment (selection bias) Unclear risk ’Materials and methods’, ’Randomisation
procedure’: ”“Each patient requiring at
least one catheter was randomly allocated
to one of two groups by drawing envelopes
from an urn.”
It was unclear who drew the envelopes and
when. It was also unclear whether the en-
velops were sealed and opaque. If the en-
velop was drawn by the investigator in-
volved in the enrolment, there was a high
risk of violating allocation concealment, for
example, by redrawing
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk ’Materials and methods’, ’Blood cultures’:
“Although it was not possible for the re-
search team to be blinded to the antisep-
tic agents used, the research microbiologist
who processed all cultures had no knowl-
edge of the antiseptic group to which the
catheter had been assigned.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Materials and methods’, ’Blood cultures’:
“Although it was not possible for the re-
search team to be blinded to the antisep-
tic agents used, the research microbiologist
who processed all cultures had no knowl-
edge of the antiseptic group to which the
catheter had been assigned.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was no information on post ran-
domisation withdrawals, nor any descrip-
tion on the use of intention-to-treat analy-
sis
Selective reporting (reporting bias) Low risk Authors reported the major outcomes
stated in the ’Methods’, namely catheter
colonisation and catheter related sepsis,
in sufficient details in the ’Results’. The
authors provided separate data for CVCs
and arterial catheters for the outcomes of
catheter colonisation per 1000 catheter-
days and catheter-related sepsis per 1000
catheter-days
Other bias Low risk None identified
Mimoz 2007
Methods Single-centre RCT (France)
Study period: 14 May 2004 to 29 June 2006
Setting: surgical ICU
Participants Adult inpatients
Number of participants: not reported
Number of catheters; 538
Age: mean age 57-58 years (SD 18-19) (reported separately in two groups)
Sex: 67.4% men in chlorhexidine group and 75.7% men in povidone-iodine group
Interventions Skin antisepsis using the following 2 regimens prior to CVC insertion and thereafter
every 72 h
1. Intervention A: chlorhexidine gluconate, 0.025% benzalkonium chloride.
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2. Intervention B: 4% benzylic alcohol combined versus 5% povidone-iodine in
70% ethanol.
Outcomes • Catheter colonisation
• Catheter-related BSI
Outcomes assessed at various points during in-patient stay.
Notes Funding source: this study was supported by Centre Hospitalier et Universitaire de
Poitiers and unrestricted grants from Bayer HealthCare and Viatris Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Methods’, ’Randomisation’: “The ran-
domisation sequences were generated by
computer and conveyed to the investiga-
tors by means of sealed envelopes, 1 for
each catheter, with instructions to select en-
velopes in numerical order.”
Allocation concealment (selection bias) Low risk ’Methods’, ’Randomisation’: “The ran-
domisation sequences were generated by
computer and conveyed to the investiga-
tors by means of sealed envelopes, 1 for
each catheter, with instructions to select en-
velopes in numerical order.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ’Methods’, ’Randomisation’: “Although it
was not possible for the nurses and attend-
ing physicians to be blinded to the antisep-
tic agent used because of different colours
of the 2 solutions (brown for the povidone-
iodine and colourless for the chlorhexidine-
based solution), the microbiologists who
processed all of the cultures and the re-
search team who reviewed the outcomes
were unaware of the type of antiseptic so-
lution used.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Methods’, ’Randomisation’: “Although it
was not possible for the nurses and attend-
ing physicians to be blinded to the antisep-
tic agent used because of different colours
of the 2 solutions (brown for the povidone-
iodine and colourless for the chlorhexidine-
based solution), the microbiologists who
processed all of the cultures and the re-
search team who reviewed the outcomes
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were unaware of the type of antiseptic so-
lution used.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was 11% withdrawal, with a similar
number of catheters excluded from anal-
ysis from the 2 groups. The authors have
clearly stated the reasons for withdrawal
and appeared to follow the intention-to-
treat principle by analysing the available pa-
tient data in the originally assigned groups
Selective reporting (reporting bias) Low risk Authors reported the 2 major outcomes
stated in the ’Methods’, namely, catheter
colonisation and catheter-related BSI, in
sufficient details in the ’Results’
Other bias Low risk None identified
Prager 1984
Methods Single-centre RCT (USA)
Study period: not reported
Setting: hospital departments ofGeneral Surgery (123),Medicine (20), Thoracic Surgery
(19), Neurosurgery (8), Obstretrics and Gynaecology (3), Paediatrics (3) and others (3)
Participants All hospital inpatients who required a CVC
Number of participants: 159 adults, 3 children
Number of catheters; 179
Age: not reported
Sex: not reported
Interventions Skin antisepsis applied daily after CVC insertion.
1. Intervention A: povidone-iodine for skin antisepsis
2. Control: no skin antisepsis
Outcomes • Catheter colonisation
• “Catheter-related septicaemia” (catheter-related BSI)
Outcomes assessed at various points during in-patient stay.
Notes Funding source: supported in part by the Purdue Frederick Company, Wilmington,
Delaware
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The exact method of sequence generated
was not described. However, in the ’Meth-
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ods’, the authors stated that patients were
randomised according to hospital registra-
tion number, suggesting that they used al-
ternation, instead of true randomisation
Allocation concealment (selection bias) High risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Although the authors did not explicitly say,
it was unlikely that the participants and the
care providers were blinded, as the study
assessed skin antisepsis versus no skin anti-
sepsis
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of microbiological outcome asses-
sor not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although the authors did not describe any
withdrawals, it appeared that all catheters
that were initially enrolled were analysed in
the originally assigned groups
Selective reporting (reporting bias) Low risk Authors reported the major outcomes of
catheter colonisation and catheter-related
BSI as stated in the ’Methods’ in sufficient
detail in the ’Results’
The authors also reported an additional
outcome of skin erythema. However, this
was reported as an overall percentage of pa-
tients with colonised catheters, not accord-
ing to the allocated groups, and so it did
not allow data extraction for meta-analysis.
Nevertheless, this did not affect our judg-
ment on the overall risk of reporting bias
in any major way
Other bias High risk There was a unit of analysis issue in which
the number of catheters analysed exceeded
the number of participants by nearly 10%,
and the outcomes were reported using
catheters as the units
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Methods Single-centre RCT (USA)
Study period: November 1982 to December 1985
Setting: surgical ICU
Participants Adult burn patients with a CVC in place
Number of participants: 50
Number of catheters; 50
Age: mean age of 5.4 years (10 weeks to 15 years)
Sex: 68% male
Interventions Skin antisepsis prior to catheter removal:
1. Intervention: 70% isopropyl alcohol applied for 3 minutes prior to catheter
removal
2. Control: no skin antisepsis
Outcomes • Catheter colonisation
• Positive blood culture (not reported according to group allocation)
Outcomes assessed at various points during in-patient stay.
Notes Funding source: not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Materials and methods’: Patients were
“randomly assigned to one of two groups”.
Method of random sequence generation
not described
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Although not stated in the article, blinding
appeared highly unlikely because the inter-
vention involved an additional measure in
catheter site care
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of microbiological outcome asses-
sor not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although not clearly stated, it appeared
that all 50 patients were analysed in their
originally assigned groups as the tabulated
results suggest
Selective reporting (reporting bias) High risk There were 2 major outcomes reported,
namely, catheter colonisation (positive
catheter tip culture) and positive blood cul-
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ture.However, the data frompositive blood
culture was unsuitable to be included in the
meta-analysis as it was reported only as an
overall figure and not according to the al-
located groups
Other bias Low risk None identified
Tuominen 1981
Methods Single-centre RCT (Finland)
Study period:not reported.
Setting: ICU
Participants Adult inpatients admitted to ICU who required a CVC. No exclusion criteria stated
Number of participants:136
Number of catheters; 136 (124 analysed)
Age: not reported
Sex: not reported
Interventions Skin antisepsis applied prior to CVC insertion and regularly thereafter
1. Intervention A: chlorhexidine 0.05% added to the sterile gauze and applied at the
CVC insertion site twice daily
2. Intervention B: sterile gauze application without chlorhexidine
Outcomes • Septicaemia
• Catheter colonisation
• Adverse effects
• Number of patients on antibiotics during the in-dwelling time of the catheters
Outcomes assessed at various points during in-patient stay.
Notes No adverse effects were recorded in either group, so we do not include the data in our
analysis
Funding source: not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Patients and methods’: The patients were
“randomly allocated to one of two groups”
Allocation concealment (selection bias) Unclear risk Not adequately described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated in the paper, but blinding
appears unlikely as the trial involved a
comparison between the application of
chlorhexidine-soaked gauze versus a dry
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sterile gauze
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of microbiological outcome asses-
sor not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The authors did not provide information
on the initial number of patients and
catheters recruited or the eventual number
analysed
Selective reporting (reporting bias) Low risk The outcomes were not defined in the
’Methods’. However, authors reported all
major outcomes, including septicaemia,
catheter colonisation and adverse effects, in
sufficient detail
Other bias Low risk None identified
Vallés 2008
Methods Single-centre RCT (Spain)
Study period: 1 Jan 2005 to 3 June 2006
Setting: adult medical-surgical ICU in a university hospital
Participants Patients requiring a CVC
Number of participants: 420
Number of catheters; 998 (631 analysed)
Age: mean age from 60 to 61 years (SD 16-17) (reported separately in three groups)
Sex: not reported.
Interventions 3-arm comparison of the following skin antiseptic regimens applied prior to CVC in-
sertion and every 72 h thereafter
1. Intervention A: 10% aqueous povidone-iodine solution.
2. Intervention B: 0.5% alcoholic chlorhexidine-gluconate solution.
3. Intervention C: 2% aqueous chlorhexidine-gluconate solution.
Outcomes • Catheter colonisation
• “Catheter related sepsis” (catheter-related BSI)
• “Catheter related bacteraemia”
• Mortality was not specified as an outcome in the methods, but mortality figures
were reported in the “Patient characteristics” table.
Outcomes assessed at various points during in-patient stay.
Notes Funding source: not stated.
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Methods’, ’Study design’: The random se-
quence was generated by “[b]y use of a
blinded block randomisation schedule”
Allocation concealment (selection bias) Unclear risk Not adequately reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Although not stated by the authors, blind-
ing to patients and caregivers appeared
highly unlikely, as the antiseptic solutions
used differed in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Methods’, ’Bacteriologic methods’:
“The microbiologists who performed the
catheter-tip cultures had no knowledge of
the antiseptic group to which the catheter
had been assigned.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Authors excluded from analysis 367/998
(36.7%) of the catheters initially ran-
domised for various reasons (Figure 1 of the
paper). They excluded 279 catheters post
enrolment because they did not meet the
inclusion criteria. However, among these
excluded catheters, the reason given for 179
of them was that they were “not cultured”.
It was unclear what the underlying reasons
were for failure to obtain culture in these
catheters, and whether the excluded data
here were missing at random
Trialists excluded 88 further catheters be-
cause they were inserted beyond 72 h af-
ter discharge from ICU. These 88 catheters
were evenly distributed among the 3 as-
signed groups (61 between the 2 chlorhex-
idine groups and 27 in the povidone-io-
dine group). However, following the con-
structionof the best- andworst-case scenar-
ios using the dropouts, the direction of the
effect estimates swung from significantly
favouring the chlorhexidine group (best-
case scenario for chlorhexidine group) to
significantly favouring the povidone-iodine
group (worst-case scenario for chlorhexi-
dine group). It was unclear whether the au-
thors followed the intention-to-treat prin-
ciple by analysing all available data accord-
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ing to the originally assigned groups, as
there was no mention of participants who
crossed over to the other group
We accorded the study high risk in this
domain due to the high absolute dropout
rate including the 179 catheters that were
not adequately accounted for, asmentioned
above, and the vulnerability of the result
estimates to best- and worst-case scenarios
Selective reporting (reporting bias) Low risk Authors reported all 3 outcomes stated
in the ’Methods’, namely, catheter coloni-
sation, catheter-related BSI (“catheter-re-
lated sepsis”) and catheter-related bacter-
aemia in sufficient detail in the ’Results’
In addition, they also reported the impor-
tant outcome of mortality in the “Patient
characteristics” table. although this was not
a pre-specified outcome in the methods.
Other bias High risk The study employed a block randomisation
schedule with high likelihood that blind-
ing of participants and personnel were not
achieved. This posed a risk to the integrity
of the random sequence, which would be
vulnerable to disruption following edu-
cated guesses by those involved in the study
on the likely assigned group of the future
participants
There was a serious unit of analysis issue in
which the number of catheters analysed ex-
ceeded the number of participants by over
50%, and the major outcomes were re-
ported using catheters as the units
Yasuda 2013
Methods Multicentre RCT (Japan)
Study period: March 2014 (not further details provided)
Setting: 23 Japanese ICUs
Participants ’Participants’: “Patients over 18 years of age undergoing CVC and AC placement for
more than 72 hours”
Number of participants:not reported
Number of catheters; 137
Age: not reported
Sex: not reported
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Yasuda 2013 (Continued)
Interventions 3-arm comparison for skin antisepsis prior to catheter insertion
1. Intervention A: 1% chlorhexidine gluconate (CHG) in alcohol.
2. Intervention B: 0.5% CHG in alcohol.
3. Intervention C: 10% povidone iodine (base solution unknown).
Outcomes • Catheter colonisation
• Catheter-related BSI
Outcomes assessed at various points during in-patient stay.
Notes For this review, we combined the data for 1% CHG and 0.5% CHG as there was no
significant difference in the results between the 2 groups
This was an interim analysis of the full study and was published in abstract form
Funding source: not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned in the published abstract
Allocation concealment (selection bias) Unclear risk Not mentioned in the published abstract
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned in the published abstract
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned in the published abstract
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not mentioned in the published abstract
Selective reporting (reporting bias) Unclear risk Not mentioned in the published abstract
Other bias Unclear risk Insufficient information in the published
abstract to assess the risks of bias
Yousefshahi 2013
Methods Single-centre RCT (Iran)
Study period: not reported.
Setting: cardiac-surgical ICU
Participants Adult patients admitted to ICU after cardiac surgery
Number of participants: 249
Number of catheters; 249
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Yousefshahi 2013 (Continued)
Age: mean age of 57 and 60 years (range 51 to 68) (reported separately in two groups)
Sex: 76.1% and 76.5% male (reported separately in two groups)
Interventions Skin antisepsis prior to CVC insertion.
1. Intervention A: Sanosil (which consisted of hydrogen peroxide and silver).
2. Intervention B: pure water (as adjunct to chlorhexidine 2% bath plus povidone-
iodine 10% scrub).
Outcomes • Catheter colonisation
• Sepsis
Outcomes assessed at various points during in-patient stay.
Notes The number of CVCs evaluated matched the number of participants
Funding source: not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk From the authors’ description, it appeared
that an alternate sequence was used follow-
ing an initial coin toss to determine the
daily order of the grouping
’Methods’: “[A]ll the patients were sep-
arated into the intervention and control
groups based on simple randomisation and
entry sequence to the pre-operation room.
Each day, a simple coin randomisation
technique was used to determine the group
for the first patient and the spraying of pure
water or Sanosil 2% on the catheter loca-
tion (from the upper chest to themandible)
. Subsequently, odd and even numbers were
used to determine the group of the other
patients.”
Allocation concealment (selection bias) High risk From the authors’ description, it appeared
that an alternate sequence was used follow-
ing an initial coin toss to determine the
daily order of the grouping
’Methods’: “[A]ll the patients were sep-
arated into the intervention and control
groups based on simple randomisation and
entry sequence to the pre-operation room.
Each day, a simple coin randomisation
technique was used to determine the group
for the first patient and the spraying of pure
water or Sanosil 2% on the catheter loca-
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Yousefshahi 2013 (Continued)
tion (from the upper chest to themandible)
. Subsequently, odd and even numbers were
used to determine the group of the other
patients.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk From the authors’ description, it appeared
that the patients and the person who re-
moved the catheters to send for culture
were blinded (see below). However, the au-
thors did not state whether the nurse who
sprayed the study substance was blinded to
the study materials
’Methods’: “Both spray bottles were similar
in shape and cover. Sanosil does not have
any colour or smell and is similar to water,
and the patients were blinded to the study.
”
’Methods’: “Each day, two trained ICU
nurses, blinded to the group type of the
patients, collected the tips of five removed
catheters aseptically...”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk It appeared that all patients recruited ini-
tially had their CVCs analysed
Selective reporting (reporting bias) Low risk Authors reported the 2 key outcomes spec-
ified in the ’Methods’, namely, catheter
colonisation and sepsis, in the ’Results’. As
no patient in either group developed sep-
sis, we did not include this outcome in our
meta-analysis
Other bias Low risk None identified
AC: arterial catheter; BSI: bloodstream infection; CHG: chlorhexidine-gluconate; CVC: central venous catheter; ICU: intensive care
unit; PA: pulmonary artery; RCT: randomised controlled trial.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Almeida 2009 Before-and-after study. Basis of exclusion: design
Apisarnthanarak 2010 Quasi-experimental before-and-after study. Basis of exclusion: design
Assadian 2004 A commentary to Parienti 2004. Basis of exclusion: article type
Astle 2005 An RCT that assessed ExSept versus chlorhexidine for patients with haemodialysis catheters. Basis of exclu-
sion: population
Balamongkhon 2007 Non-randomised trial that assessedCVC site care using 2% chlorhexidine gluconate versus povidone-iodine.
Basis of exclusion: design
Bilir 2009 This is a conference abstract of an study awaiting classification (BIlir 2013)
Borghesi 2011 A review article on infection control strategies for the newborn. Basis of exclusion: article type and population
Bowling 2010 A before-and-after study that assessed a multifaceted programme in decreasing blood culture contamination.
Basis of exclusion: study design
Camins 2010 Cross-over study that assessed chlorhexidine-impregnated foam dressing for prevention of catheter-related
BSI in patients undergoing haemodialysis. Basis of exclusion: design, population and intervention
Carrer 2005 RCT that compared maximal sterile barrier (consisting of mask, cap, sterile gloves, gown, large drape) versus
control precautions (mask, cap, sterile gloves, small drape) and transparent polyurethane film versus gauze
dressing for reduction of CVC-related infections. Basis of exclusion: intervention
Casey 2003 A single-centre RCT (UK) that compared the PosiFlow needleless connector against the standard luer
cap attached to the CVCs for adult patients admitted for cardiac surgery. The authors used a factorial
design which enabled the concurrent 3-arm comparison of 3 different skin antiseptic solutions (0.5%
chlorhexidine/alcohol, 70% isopropyl alcohol and 10% povidone-iodine) applied prior to the insertion of
the catheters. However, the major outcome assessed was “stopcock entry port microbial contamination”
rather than catheter colonisation, and this is not part of the prespecified outcomes in our review. Basis of
exclusion: study design (design of the outcome)
Casey 2007 RCT that compared a needless connector set (Clearlink Y-type extension set) against standard 3-way stop-
cocks with caps for reducing CVC related infections. Basis of exclusion: intervention
Cepkova 2006 A review article on reducing catheter-related infections in the ICU. Basis of exclusion: article type
Chaiyakunapruk 2003 Cost-effectiveness analysis on chlorhexidine gluconate versus povidone-iodine for catheter site care. Basis
of exclusion: article type
Crawford 2004 Cost-benefit analysis of chlorhexidine gluconate dressing in reducing catheter-related infections. Basis of
exclusion: article type
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Daghistani 1996 RCT that assessed antibiotic flush for CVCs in children with cancer. Basis of exclusion: intervention
Darouiche 2007 A review article on strategies to prevent catheter-related infections. Basis of exclusion: article type
Darouiche 2008 A review article on strategies to prevent catheter-related infections. Basis of exclusion: article type
Dean 2011 A cross-over study that compared the use of chlorhexidine solution against chlorhexidine-impregnated cloth
for CVC care. Basis of exclusion: study design
Dettenkofer 2002 A quasi-randomised trial in which patients were assigned on an alternate basis to either octenidine-based skin
antiseptic solution versus propanol-based solution. Additionally, the results were presented in 25th centile,
median and 75th centile of quantitative skin culture (in CFU/24 cm2) which does not allow extraction for
meta-analysis. Basis of exclusion: study design and data reporting
Eggimann 2010 A prospective non-randomised study that assessed catheter-related infections following the introduction of
various infection control strategies. Basis of exclusion: study design
Eyberg 2008 RCT that assessed chlorhexidine gluconate gel dressing versus chlorhexidine gluconate disk in reducing
CVC-related infections. Basis of exclusion: intervention
Freiberger 1992 A quasi-experimental study comparing 2 skin antisepsis regimens (chlorhexidine and povidone-iodine) and
2 types of dressing (Tegaderm and standard gauze) in a 4-arm comparison of different combinations. The
authors only reported the results in F or X2 values along with the P values, without reporting the raw data,
which precluded data extraction for meta-analysis. Basis of exclusion: study design and data reporting
Fukunaga 2004 A non-randomised study with historical cohort that assessed povidone-iodine ointment in addition to
dressing in reducing CVC-related infections. Basis of exclusion: study design
Garcia 2010 A non-randomised study that assessed the effect of chlorhexidine scrub of the CVC hub during each access
in reducing CVC-related infections. Basis of exclusion: study design
Garcia-Teresa 2007 A multicentre observational study that evaluated CVC-related infections in children. Basis of exclusion:
study design
Garcia-Vazquez 2011 A before-and-after study that evaluated the effect of a hand hygiene promotion programme in reducing
infections in an ICU. Basis of exclusion: study design
Garland 1996 An RCT that assessed the local reaction to a chlorhexidine gluconate-impregnated antimicrobial dressing
in very low birth weight infants. Basis of exclusion: population and intervention
Garland 2001 An RCT that compared chlorhexidine gluconate-impregnated dressing with povidone-iodine skin scrub for
prevention of CVC-related infections in neonates. Basis of exclusion: population
Garland 2009a An RCT that compared chlorhexidine gluconate with povidone-iodine as skin antisepsis prior to CVC
placement in neonates. Basis of exclusion: population
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Garland 2009b An RCT that assessed the safety of chlorhexidine gluconate in neonates with percutaneously inserted central
venous catheters. Basis of exclusion: population
Gilad 2006 A review article on prevention of catheter-related BSI in the neonatal intensive care setting. Basis of exclusion:
article type
Girard 2012 A longitudinal cohort study that compared two CVC cleaning protocols (containing alcohol-based povi-
done-iodine solution (Betadine alcolique) and chlorhexidine-based antiseptic (Biseptine), respectively) ad-
ministered in different periods. Basis of exclusion: study design
Gnass 2004 A prospective, non-randomised study that evaluated the effect of multiple infection control strategies in
reducing catheter-related infections. Basis of exclusion: study design
Gunst 2011 A non-randomised trial that compared antiseptic-impregnated CVC with peripherally-inserted central line
in reducing catheter-related infections. Basis of exclusion: study design and intervention
Habibzadeh 2013 A commentary on an included study (Yousefshahi 2013)
Hachem 2002 A review article on prevention of catheter-related infection in long-term catheters. Basis of exclusion: article
type
Halpin 1991 An RCT that evaluated the effect of povidone-iodine connection shield that is incorporated in the catheter
hub in reducing CVC-related infections. Basis of exclusion: intervention
Hanazaki 1999 An RCT that assessed the effect of chlorhexidine dressing in reducing catheter colonisation. Basis of exclu-
sion: intervention
Hill 1990 AnRCT that assessed the effect ofmupirocin ointment on colonisation rate of internal jugular vein catheters.
Basis of exclusion: intervention
Huang 2006 A retrospective study that assessed the effect ofmultiple infection controlmeasures on the rates ofmethicillin-
resistant Staphylococcus aureus infection in an adult ICU. Basis of exclusion: study design
Hutchinson 1990 An RCT that assessed occlusive versus non-occlusive right atrial catheter dressing change procedures in
children with cancer. Basis of exclusion: intervention
Ishikawa 2010 An RCT comparing maximal sterile barrier precaution versus standard sterile barrier precaution measures
during CVC insertion in reducing CVC-related infections. Basis of exclusion: intervention
Ishizuka 2009 A non-randomised trial that compared the use of chlorhexidine versus povidone-iodine for CVC site skin
disinfection in 2 separate cohorts of patients. Basis of exclusion: study design
Johnson 2005 An RCT that compared honey versus mupirocin applied at the catheter exit site for preventing catheter-
related infections in patients undergoing haemodialysis. Basis of exclusion: population and intervention
Khattak 2010 An RCT that evaluated the absorption of silver in very low birthweight infants who received silver alginate-
impregnated central venous catheter. Basis of exclusion: population and intervention
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Khouli 2009 A conference abstract that reports the impact of simulation training on residents’ performance in adhering
to maximum sterile barrier precaution during CVC insertion. Basis of exclusion: research question and
design
Krein 2007 A national survey on measures to reduce catheter-related BSI. Basis of exclusion: study design
Kruse 1999 This is a commentary on an included study (Mimoz 1996). Basis of exclusion: article type
Kulkarni 2013 An RCT that compared the use of 10% povidone-iodine versus 2% chlorhexidine for skin disinfection prior
to insertion of epidural or central venous catheters. The study combined both epidural and CVCs is the
outcome reporting with no separate data for CVC, and more importantly, the outcome of skin colonisation
was assessed based on a skin swab that was taken immediately after the application of the skin antiseptic
agent, which did not fit in with our question of whether the application of skin antiseptic agent reduces
catheter-related infection during the period of catheter use. Excluded on th basis of research question and
design
Lange 1997 A non-randomised trial that assessed a multifaceted strategy in CVC management in reducing catheter-
related infection in children with chronic illness. Basis of exclusion: study design
Le Corre 2003 An RCT comparing transparent dressing versus a dry gauze applied at the exit site of the catheter on
haemodialysis patients. Basis of exclusion: population and intervention
Legras 1997 An RCT comparing alcohol-chlorhexidine against povidone-iodine for skin antisepsis for intravascular
catheters. The study evaluated a mixture of venous, arterial and Swan Gantz catheters with no separate
outcome reporting for venous catheters. There were no contact details provided in the paper to request for
separate data for venous catheters. Basis of exclusion: insufficient information
Levy 2005 An RCT that assessed the effectiveness of chlorhexidine gluconate-impregnated dressing in reducing
catheter-related infections in children. Basis of exclusion: intervention
Madeo 1998 An RCT comparing 2 different dressings for arterial and venous catheters in reducing catheter-related
infections. Basis of exclusion: intervention
Mahieu 2001 A prospective cohort study that evaluated the effect of catheter manipulation on catheter-related BSI in
neonates. Basis of exclusion: study design, population and intervention
Maki 1981 A commentary on disinfectant for vascular catheters. Basis of exclusion: article type
Maki 1992 An RCT comparing different antibiotic ointments for preventing catheter-related infection. Basis of exclu-
sion: intervention
McCann 2016 A pilot RCT involving in 3 Irish outpatient hemodialysis units compared 2% chlorhexidine gluconate
(CHG) in 70% isopropyl alcohol with CHG solutions for central venous catheter exit site antisepsis. Basis
of exclusion: population
Montecalvo 2012 A prospective cohort study that evaluated the rates of catheter-related BSI over 3 study periods: pre-
intervention (phase 1), in which all patients were bathed with soap and water or non-medicated washcloths;
active intervention (phase 2), in which patients were bathed with 2% chlorhexidine gluconate cloths with
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the number of baths administered and skin tolerability assessed; and post-intervention (phase 3), in which
chlorhexidine bathing continued but without oversight by research personnel. Basis of exclusion: study
design
Munoz-Price 2009 A non-randomised study that evaluated a step-wise infection control approach in reducing catheter-related
infection. Basis of exclusion: study design, intervention
Munoz-Price 2012 A non-randomised study that evaluated the use of daily chlorhexidine bath in reducing catheter-related
infection. Basis of exclusion: study design
Nikoletti 1999 An RCT comparing transparent polyurethane and hydrocolloid dressings for CVC in reducing catheter-
related infection. Basis of exclusion: intervention
Noto 2014 A cluster-RCT that assessed the effects of daily chlorhexidine bathing on the rates of healthcare associated
infection in general for all ICU patients, not specific to patients with CVC in place. Basis of exclusion:
population
Parienti 2004 A cluster-randomised cross-over study that assessed the effectiveness of alcoholic povidone-iodine in pre-
venting catheter-related infection. Basis of exclusion: study design
Peterson 2011 An evidence-based summary on the effectiveness of chlorhexidine versus 70% alcohol for CVC injection
cap disinfection. Basis of exclusion: article type
Raad 1994 An RCT that assessed the effectiveness of maximal sterile precaution during CVC insertion in reducing
catheter-related infection. Basis of exclusion: intervention
Render 2006 A cluster-randomised trial that assessed the effectiveness of 2 multifaceted infection control projects in
reducing central line infections. Basis of exclusion: study design
Rezaei 2009 An RCT that assessed the effectiveness of mupirocin ointment in reducing catheter-related infection. Basis
of exclusion: intervention
Richardson 2006 A commentary on Parienti 2004. Basis of exclusion: article type
Rickard 2004 An RCT that assessed the effectiveness of changing intravenous administration set for reducing catheter-
related infection. Basis of exclusion: intervention
Rijnders 2003 An RCT that assessed the use of full sterile barrier precaution in reducing catheter-related infection. Basis
of exclusion: intervention
Rubinson 2004 A review article onmeasures to reduce catheter-related infection during insertion of CVC. Basis of exclusion:
article type
Rupp 2008 A non-randomised, comparative, cross-over trial that evaluated the effectiveness of alcohol-based hand gel
in reducing hospital-acquired infections. Basis of exclusion: research question, study design
Ruschulte 2009 An RCT that assessed the effectiveness of chlorhexidine-impregnated wound dressing in reducing CVC-
related infection in patients undergoing chemotherapy. Basis of exclusion: intervention
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Schwebel 2012 An economic analysis on chlorhexidine-impregnated sponges for reducing catheter-related infection. Basis
of exclusion: article type
Sheehan 1993 An article identified through a related review paper in the form of a conference abstract. The text of the
conference abstract could not be traced after contacting the author of the review article. We were unable
to locate the contact details of the authors of this conference paper to request for further information. The
conference abstract did not appear to be published subsequently in full. Basis of exclusion: insufficient
information
Spiegler 2010 A review article comparing central venous line and arterial line infections. Basis of exclusion: article type
Swan 2014 A cluster-RCT that compared chlorhexidine bathing versus soap and water bathing in decreasing the rates
of healthcare associated infection for all patients in ICUs, and not only patients with a CVC in place. Basis
of exclusion: population
Tietz 2005 A prospective observational study that assessed the effectiveness of octenidine hydrochloride for CVC site
care in patients receiving bone marrow transplant. Basis of exclusion: study design
Van Esch 2002 An evidence-based summary that examined the role of chlorhexidine versus povidone-iodine antisepsis for
reducing catheter-related infection in neonates. Basis of exclusion: article type
Zingg 2008 An overview on catheter-related BSI. Basis of exclusion: article type
Zingg 2009 A before-and-after study that assessed the effectiveness of an educational programme on promoting hand
hygiene measures in reducing catheter-related BSI. Basis of exclusion: study design
BSI: bloodstream infection; CFU: colony-forming units; CVC: central venous catheter; RCT: randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Atahan 2012
Methods RCT (Czech Republic)
Participants Adult surgical patients who required a CVC
Interventions CVC insertion site disinfection with 10% povidone-iodine (Poviiodeks) versus Savlosol (15% cetrimide, 1.5%
chlorhexidine-gluconate, ethanol)
Outcomes Catheter colonisation and catheter-related BSI
Notes -
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BIlir 2013
Methods RCT (Turkey)
Participants Adult ICU patients who required a CVC
Interventions 3-arm comparison: skin antisepsis using 4% chlorhexidine gluconate (n = 19), 10% povidone iodine (n = 19) or
octenidine hydrochlorodine (n = 19)
Outcomes Catheter colonisation and catheter-related BSI (“catheter-related sepsis”), determined using “standardmicrobiological
methods” (’Materials and methods’)
Notes The study evaluated a mixture of venous and arterial catheters with no separate analysis for venous catheters. This
appears to be a conference abstract. We are awaiting further information from the authors
Giles 2002
Methods RCT
Participants Surgical patients who required a CVC
Interventions Transparent occlusive dressing versus daily CVC site care with povidone-iodine 10% solution
Outcomes Catheter colonisation and catheter-related sepsis
Notes Awaiting full text
Knasinski 2000
Methods RCT
Participants Unclear
Interventions 1% chlorhexidine plus 75% alcohol versus 10% povidone iodine for cutaneous disinfection and follow-up site care
with central venous and arterial catheters
Outcomes Catheter colonisation and catheter-related BSI
Notes This title was identified as a conference abstract from an earlier meta-analysis on a similar topic. There is no further
information at this stage other than the title. The author of the meta-analysis paper with the title could not locate
the abstract paper, and the study appeared not to be subsequently published in full. The study included both venous
and arterial catheters, and it was unclear whether a separate outcome report for venous catheters would be available.
We are awaiting the response of the study author for further information
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Mimoz 2015
Methods Open-label multi-centre RCT with a two-by-two factorial design
Participants Adults (age >/=18 years) admitted to one of 11 French intensive-care units and requiring at least one of central-
venous, haemodialysis, or arterial catheters
Interventions All intravascular catheters prepared with 2% chlorhexidine-70% isopropyl alcohol (chlorhexidine-alcohol) or 5%
povidone iodine-69% ethanol (povidone iodine-alcohol), with or without scrubbing of the skin with detergent before
antiseptic application
Outcomes “catheter-related infections”, catheter colonisation, adverse effects
Notes Awaiting full-text report for specific information on central venous catheters
Yamamoto 2014
Methods A comparative study (it is unclear from the abstract whether it is an RCT)
Participants Haematology patients (age range unclear)
Interventions 1% chlorhexidine-gluconate ethanol versus 10% povidone-iodine for skin antisepsis of CVC sites
Outcomes Catheter-related BSI, catheter colonisation
Notes Awaiting full text from the authors
Characteristics of ongoing studies [ordered by study ID]
Goudet 2013
Trial name or title Comparison of four skin preparation strategies to prevent catheter-related infection in intensive care unit
(CLEAN trial): a study protocol for a randomized controlled trial
Methods “A prospective multicenter, 2 × 2 factorial, randomized-controlled, assessor-blind trial”
Participants Setting: 11 intensive care units in 6 French hospitals. Participants: All adult patients aged over 18 years
requiring the insertion of 1 or more of the following: peripheral arterial catheter, non-tunnelled central venous
catheter, haemodialysis catheter and arterial pulmonary catheter
Interventions Patients are allocated to 1 of the 4 skin preparation strategies: 2% chlorhexidine/70% isopropyl alcohol or
5% povidone iodine/69% ethanol, with and without prior skin scrubbing
Outcomes Catheter-related BSI, catheter colonisation, cutaneous tolerance, length of hospitalisation, mortality and cost
Starting date October 2012, lasting approximately 14 months
Contact information Corresponding author: Olivier Mimoz o.mimoz@chu-poitiers.fr
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Notes Clinicaltrials.gov number NCT01629550. Protocol published in Trials, 2013:14: 114
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D A T A A N D A N A L Y S E S
Comparison 1. Povidone-iodine (in aqueous solution) versus no skin antisepsis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter-related BSI 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.37, 2.61]
2 Catheter colonisation 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.53, 1.60]
Comparison 2. Chlorhexidine (in aqueous solution) versus no skin antisepsis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Septicaemia 1 136 Risk Ratio (M-H, Fixed, 95% CI) 2.91 [0.31, 27.31]
2 Catheter colonisation 1 124 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.61, 2.59]
3 Number of patients who
required antibiotics during
in-dwelling period of catheter
1 136 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.55, 1.27]
Comparison 3. Alcohol versus no skin antisepsis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter colonisation 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.30, 1.85]
Comparison 4. Chlorhexidine versus povidone-iodine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter-related BSI 4 1436 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.41, 0.99]
1.1 Chlorhexidine in
aqueous solution versus
povidone-iodine in aqueous
solution
2 452 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.32, 1.28]
1.2 Chlorhexidine in alcohol
versus povidone-iodine in
aqueous solution
2 503 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.39, 1.53]
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1.3 Chlorhexidine in alcohol
versus povidone-iodine in
alcohol
1 481 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.13, 1.24]
2 Catheter-related BSI per 1000
catheter-days
4 1450 Risk Ratio (Fixed, 95% CI) 0.53 [0.30, 0.94]
2.1 Chlorhexidine in
aqueous solution versus
povidone-iodine in aqueous
solution
1 308 Risk Ratio (Fixed, 95% CI) 0.82 [0.23, 2.93]
2.2 Chlorhexidine in alcohol
versus povidone-iodine in
aqueous solution
3 661 Risk Ratio (Fixed, 95% CI) 0.49 [0.25, 0.95]
2.3 Chlorhexidine in alcohol
versus povidone-iodine in
alcohol
1 481 Risk Ratio (Fixed, 95% CI) 0.41 [0.06, 2.92]
3 All-cause mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Chlorhexidine in
aqueous solution versus
povidone-iodine in aqueous
solution
1 213 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.72, 1.83]
3.2 Chlorhexidine in alcohol
versus povidone-iodine in
aqueous solution
1 222 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.48, 1.34]
4 Catheter colonisation 5 1533 Risk Difference (M-H, Fixed, 95% CI) -0.08 [-0.12, -0.03]
4.1 Chlorhexidine in
aqueous solution versus
povidone-iodine in aqueous
solution
2 452 Risk Difference (M-H, Fixed, 95% CI) -0.09 [-0.17, -0.02]
4.2 Chlorhexidine in alcohol
versus povidone-iodine in
aqueous solution
3 600 Risk Difference (M-H, Fixed, 95% CI) -0.04 [-0.11, 0.03]
4.3 Chlorhexidine in alcohol
versus povidone-iodine in
alcohol
1 481 Risk Difference (M-H, Fixed, 95% CI) -0.11 [-0.17, -0.04]
5 Catheter colonisation per 1000
catheter-days
5 1547 Risk Ratio (Fixed, 95% CI) 0.64 [0.50, 0.81]
5.1 Chlorhexidine in
aqueous solution versus
povidone-iodine in aqueous
solution
1 308 Risk Ratio (Fixed, 95% CI) 0.69 [0.40, 1.20]
5.2 Chlorhexidine in alcohol
versus povidone-iodine in
aqueous solution
4 758 Risk Ratio (Fixed, 95% CI) 0.64 [0.48, 0.85]
5.3 Chlorhexidine in alcohol
versus povidone-iodine in
alcohol
1 481 Risk Ratio (Fixed, 95% CI) 0.53 [0.24, 1.17]
6 Insertion site infection 1 242 Mean Difference (IV, Fixed, 95% CI) -2.80 [-9.10, 3.50]
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Comparison 5. Chlorhexidine (in aqueous solution) versus alcohol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter-related BSI 1 99 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.02, 2.54]
2 Catheter colonisation 1 99 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.11, 1.33]
Comparison 6. Povidone-iodine (in aqueous solution) versus alcohol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter-related BSI 1 109 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.21, 5.08]
2 Catheter colonisation 2 169 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [0.76, 4.09]
2.1 Povidone-iodine in
aqueous solution versus alcohol
1 109 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.49, 3.14]
2.2
Povidone-iodine-impregnated
adherent film versus alcohol
1 60 Risk Ratio (M-H, Fixed, 95% CI) 9.0 [0.51, 160.17]
Comparison 7. Alcohol versus octenidine in alcohol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter-related BSI 1 387 Risk Ratio (M-H, Fixed, 95% CI) 2.01 [0.88, 4.59]
2 Catheter-related BSI per 1000
catheter-days
1 387 Risk Ratio (Fixed, 95% CI) 2.18 [0.54, 8.77]
3 Catheter colonisation 1 322 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [1.22, 4.21]
4 Catheter colonisation per 1000
catheter-days
1 322 Risk Ratio (Fixed, 95% CI) 2.23 [0.79, 6.29]
5 Skin colonisation 1 365 Mean Difference (IV, Fixed, 95% CI) 79.00 [32.76, 125.
24]
6 Adverse effects 1 398 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.60, 1.20]
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Comparison 8. Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus chlorhexidine (in
alcohol)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter colonisation 1 88 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.04, 0.81]
2 Catheter colonisation per 1000
catheter-days
1 88 Risk Ratio (Fixed, 95% CI) 0.19 [0.06, 0.59]
Comparison 9. Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus povidone-iodine
(in aqueous solution)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter colonisation 1 95 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.04, 0.62]
2 Catheter colonisation per 1000
catheter-days
1 95 Risk Ratio (Fixed, 95% CI) 0.17 [0.05, 0.52]
Comparison 10. Sanosil (hydrogen peroxide and silver) versus water as adjunct to chlorhexidine 2% aqueous
bath plus povidone-iodine aqueous 10% scrub
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter colonisation 1 249 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.68, 1.72]
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Analysis 1.1. Comparison 1 Povidone-iodine (in aqueous solution) versus no skin antisepsis, Outcome 1
Catheter-related BSI.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 1 Povidone-iodine (in aqueous solution) versus no skin antisepsis
Outcome: 1 Catheter-related BSI
Study or subgroup Povidone iodine No skin antisepsis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prager 1984 7/84 8/95 100.0 % 0.99 [ 0.37, 2.61 ]
Total (95% CI) 84 95 100.0 % 0.99 [ 0.37, 2.61 ]
Total events: 7 (Povidone iodine), 8 (No skin antisepsis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours povidone iodine Favours control
Analysis 1.2. Comparison 1 Povidone-iodine (in aqueous solution) versus no skin antisepsis, Outcome 2
Catheter colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 1 Povidone-iodine (in aqueous solution) versus no skin antisepsis
Outcome: 2 Catheter colonisation
Study or subgroup Povidone iodine No skin antisepsis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prager 1984 18/84 22/95 100.0 % 0.93 [ 0.53, 1.60 ]
Total (95% CI) 84 95 100.0 % 0.93 [ 0.53, 1.60 ]
Total events: 18 (Povidone iodine), 22 (No skin antisepsis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours povidone iodine Favours control
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Analysis 2.1. Comparison 2 Chlorhexidine (in aqueous solution) versus no skin antisepsis, Outcome 1
Septicaemia.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 2 Chlorhexidine (in aqueous solution) versus no skin antisepsis
Outcome: 1 Septicaemia
Study or subgroup Chlorhexidine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tuominen 1981 3/69 1/67 100.0 % 2.91 [ 0.31, 27.31 ]
Total (95% CI) 69 67 100.0 % 2.91 [ 0.31, 27.31 ]
Total events: 3 (Chlorhexidine), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chlorhexidine Favours control
Analysis 2.2. Comparison 2 Chlorhexidine (in aqueous solution) versus no skin antisepsis, Outcome 2
Catheter colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 2 Chlorhexidine (in aqueous solution) versus no skin antisepsis
Outcome: 2 Catheter colonisation
Study or subgroup Chlorhexidine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tuominen 1981 13/60 11/64 100.0 % 1.26 [ 0.61, 2.59 ]
Total (95% CI) 60 64 100.0 % 1.26 [ 0.61, 2.59 ]
Total events: 13 (Chlorhexidine), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chlorhexidine Favours control
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Analysis 2.3. Comparison 2 Chlorhexidine (in aqueous solution) versus no skin antisepsis, Outcome 3
Number of patients who required antibiotics during in-dwelling period of catheter.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 2 Chlorhexidine (in aqueous solution) versus no skin antisepsis
Outcome: 3 Number of patients who required antibiotics during in-dwelling period of catheter
Study or subgroup Chlorhexidine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tuominen 1981 25/69 29/67 100.0 % 0.84 [ 0.55, 1.27 ]
Total (95% CI) 69 67 100.0 % 0.84 [ 0.55, 1.27 ]
Total events: 25 (Chlorhexidine), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chlorhexidine Favours control
Analysis 3.1. Comparison 3 Alcohol versus no skin antisepsis, Outcome 1 Catheter colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 3 Alcohol versus no skin antisepsis
Outcome: 1 Catheter colonisation
Study or subgroup Alcohol-based No skin antisepsis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sadowski 1988 6/25 8/25 100.0 % 0.75 [ 0.30, 1.85 ]
Total (95% CI) 25 25 100.0 % 0.75 [ 0.30, 1.85 ]
Total events: 6 (Alcohol-based), 8 (No skin antisepsis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alcohol-based Favours no antisepsis
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Analysis 4.1. Comparison 4 Chlorhexidine versus povidone-iodine, Outcome 1 Catheter-related BSI.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 4 Chlorhexidine versus povidone-iodine
Outcome: 1 Catheter-related BSI
Study or subgroup Chlorhexidine-based
Povidone-
iodine-
based Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Chlorhexidine in aqueous solution versus povidone-iodine in aqueous solution
Maki 1991 1/67 5/77 10.3 % 0.23 [ 0.03, 1.92 ]
Vall s 2008 17/211 10/97 30.4 % 0.78 [ 0.37, 1.64 ]
Subtotal (95% CI) 278 174 40.7 % 0.64 [ 0.32, 1.28 ]
Total events: 18 (Chlorhexidine-based), 15 (Povidone-iodine-based)
Heterogeneity: Chi2 = 1.17, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Chlorhexidine in alcohol versus povidone-iodine in aqueous solution
Humar 2000 4/92 4/88 9.1 % 0.96 [ 0.25, 3.71 ]
Vall s 2008 15/226 9/97 27.9 % 0.72 [ 0.32, 1.58 ]
Subtotal (95% CI) 318 185 37.0 % 0.77 [ 0.39, 1.53 ]
Total events: 19 (Chlorhexidine-based), 13 (Povidone-iodine-based)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
3 Chlorhexidine in alcohol versus povidone-iodine in alcohol
Mimoz 2007 4/242 10/239 22.3 % 0.40 [ 0.13, 1.24 ]
Subtotal (95% CI) 242 239 22.3 % 0.40 [ 0.13, 1.24 ]
Total events: 4 (Chlorhexidine-based), 10 (Povidone-iodine-based)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Total (95% CI) 838 598 100.0 % 0.64 [ 0.41, 0.99 ]
Total events: 41 (Chlorhexidine-based), 38 (Povidone-iodine-based)
Heterogeneity: Chi2 = 2.28, df = 4 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.046)
Test for subgroup differences: Chi2 = 0.98, df = 2 (P = 0.61), I2 =0.0%
0.01 0.1 1 10 100
Favours chlorhexidine Favours povidone-iodine
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Analysis 4.2. Comparison 4 Chlorhexidine versus povidone-iodine, Outcome 2 Catheter-related BSI per
1000 catheter-days.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 4 Chlorhexidine versus povidone-iodine
Outcome: 2 Catheter-related BSI per 1000 catheter-days
Study or subgroup Chlorhexidine-based
Povidone-
iodine-
based log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Chlorhexidine in aqueous solution versus povidone-iodine in aqueous solution
Vall s 2008 211 97 -0.2 (0.65) 20.1 % 0.82 [ 0.23, 2.93 ]
Subtotal (95% CI) 211 97 20.1 % 0.82 [ 0.23, 2.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
2 Chlorhexidine in alcohol versus povidone-iodine in aqueous solution
Humar 2000 92 88 -0.12 (0.7) 17.3 % 0.89 [ 0.22, 3.50 ]
Mimoz 1996 87 71 -1.34 (0.5) 34.0 % 0.26 [ 0.10, 0.70 ]
Vall s 2008 226 97 -0.2 (0.65) 20.1 % 0.82 [ 0.23, 2.93 ]
Subtotal (95% CI) 405 256 71.4 % 0.49 [ 0.25, 0.95 ]
Heterogeneity: Chi2 = 2.91, df = 2 (P = 0.23); I2 =31%
Test for overall effect: Z = 2.10 (P = 0.036)
3 Chlorhexidine in alcohol versus povidone-iodine in alcohol
Mimoz 2007 242 239 -0.89 (1) 8.5 % 0.41 [ 0.06, 2.92 ]
Subtotal (95% CI) 242 239 8.5 % 0.41 [ 0.06, 2.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Total (95% CI) 858 592 100.0 % 0.53 [ 0.30, 0.94 ]
Heterogeneity: Chi2 = 3.49, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Chi2 = 0.58, df = 2 (P = 0.75), I2 =0.0%
0.01 0.1 1 10 100
Favours chlorhexidine Favours povidone-iodine
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Analysis 4.3. Comparison 4 Chlorhexidine versus povidone-iodine, Outcome 3 All-cause mortality.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 4 Chlorhexidine versus povidone-iodine
Outcome: 3 All-cause mortality
Study or subgroup Chlorhexidine-based
Povidone-
iodine-
based Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Chlorhexidine in aqueous solution versus povidone-iodine in aqueous solution
Vall s 2008 29/107 25/106 100.0 % 1.15 [ 0.72, 1.83 ]
Subtotal (95% CI) 107 106 100.0 % 1.15 [ 0.72, 1.83 ]
Total events: 29 (Chlorhexidine-based), 25 (Povidone-iodine-based)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 Chlorhexidine in alcohol versus povidone-iodine in aqueous solution
Vall s 2008 22/116 25/106 100.0 % 0.80 [ 0.48, 1.34 ]
Subtotal (95% CI) 116 106 100.0 % 0.80 [ 0.48, 1.34 ]
Total events: 22 (Chlorhexidine-based), 25 (Povidone-iodine-based)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 1.04, df = 1 (P = 0.31), I2 =3%
0.01 0.1 1 10 100
Favours chlorhexidine Favours povidone-iodine
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Analysis 4.4. Comparison 4 Chlorhexidine versus povidone-iodine, Outcome 4 Catheter colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 4 Chlorhexidine versus povidone-iodine
Outcome: 4 Catheter colonisation
Study or subgroup Chlorhexidine-based
Povidone-
iodine-
based
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Chlorhexidine in aqueous solution versus povidone-iodine in aqueous solution
Maki 1991 4/67 15/77 10.0 % -0.14 [ -0.24, -0.03 ]
Vall s 2008 38/211 24/97 18.5 % -0.07 [ -0.17, 0.03 ]
Subtotal (95% CI) 278 174 28.5 % -0.09 [ -0.17, -0.02 ]
Total events: 42 (Chlorhexidine-based), 39 (Povidone-iodine-based)
Heterogeneity: Chi2 = 0.89, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
2 Chlorhexidine in alcohol versus povidone-iodine in aqueous solution
Humar 2000 31/92 24/88 12.5 % 0.06 [ -0.07, 0.20 ]
Langgartner 2004 11/45 16/52 6.7 % -0.06 [ -0.24, 0.11 ]
Vall s 2008 34/226 24/97 18.9 % -0.10 [ -0.19, 0.00 ]
Subtotal (95% CI) 363 237 38.1 % -0.04 [ -0.11, 0.03 ]
Total events: 76 (Chlorhexidine-based), 64 (Povidone-iodine-based)
Heterogeneity: Chi2 = 3.71, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.03 (P = 0.30)
3 Chlorhexidine in alcohol versus povidone-iodine in alcohol
Mimoz 2007 28/242 53/239 33.4 % -0.11 [ -0.17, -0.04 ]
Subtotal (95% CI) 242 239 33.4 % -0.11 [ -0.17, -0.04 ]
Total events: 28 (Chlorhexidine-based), 53 (Povidone-iodine-based)
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0017)
Total (95% CI) 883 650 100.0 % -0.08 [ -0.12, -0.03 ]
Total events: 146 (Chlorhexidine-based), 156 (Povidone-iodine-based)
Heterogeneity: Chi2 = 6.43, df = 5 (P = 0.27); I2 =22%
Test for overall effect: Z = 3.60 (P = 0.00032)
Test for subgroup differences: Chi2 = 1.96, df = 2 (P = 0.38), I2 =0.0%
-1 -0.5 0 0.5 1
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Analysis 4.5. Comparison 4 Chlorhexidine versus povidone-iodine, Outcome 5 Catheter colonisation per
1000 catheter-days.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 4 Chlorhexidine versus povidone-iodine
Outcome: 5 Catheter colonisation per 1000 catheter-days
Study or subgroup Chlorhexidine-based
Povidone-
iodine-
based log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Chlorhexidine in aqueous solution versus povidone-iodine in aqueous solution
Vall s 2008 211 97 -0.37 (0.28) 19.4 % 0.69 [ 0.40, 1.20 ]
Subtotal (95% CI) 211 97 19.4 % 0.69 [ 0.40, 1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 Chlorhexidine in alcohol versus povidone-iodine in aqueous solution
Humar 2000 92 88 -0.3 (0.23) 28.7 % 0.74 [ 0.47, 1.16 ]
Langgartner 2004 45 52 -0.13 (0.32) 14.8 % 0.88 [ 0.47, 1.64 ]
Mimoz 1996 87 71 -1.35 (0.4) 9.5 % 0.26 [ 0.12, 0.57 ]
Vall s 2008 226 97 -0.47 (0.29) 18.1 % 0.63 [ 0.35, 1.10 ]
Subtotal (95% CI) 450 308 71.1 % 0.64 [ 0.48, 0.85 ]
Heterogeneity: Chi2 = 6.49, df = 3 (P = 0.09); I2 =54%
Test for overall effect: Z = 3.06 (P = 0.0022)
3 Chlorhexidine in alcohol versus povidone-iodine in alcohol
Mimoz 2007 242 239 -0.63 (0.4) 9.5 % 0.53 [ 0.24, 1.17 ]
Subtotal (95% CI) 242 239 9.5 % 0.53 [ 0.24, 1.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.12)
Total (95% CI) 903 644 100.0 % 0.64 [ 0.50, 0.81 ]
Heterogeneity: Chi2 = 6.78, df = 5 (P = 0.24); I2 =26%
Test for overall effect: Z = 3.65 (P = 0.00026)
Test for subgroup differences: Chi2 = 0.28, df = 2 (P = 0.87), I2 =0.0%
0.01 0.1 1 10 100
Favours chlorhexidine Favours povidone-iodine
77Skin antisepsis for reducing central venous catheter-related infections (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.6. Comparison 4 Chlorhexidine versus povidone-iodine, Outcome 6 Insertion site infection.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 4 Chlorhexidine versus povidone-iodine
Outcome: 6 Insertion site infection
Study or subgroup Chlorhexidine-based
Povidone-
iodine-
based
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[mean
CFU] N
Mean(SD)[mean
CFU] IV,Fixed,95% CI IV,Fixed,95% CI
Humar 2000 125 3.1 (21.2) 117 5.9 (28.1) 100.0 % -2.80 [ -9.10, 3.50 ]
Total (95% CI) 125 117 100.0 % -2.80 [ -9.10, 3.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours chlorhexidine Favours povidone iodine
Analysis 5.1. Comparison 5 Chlorhexidine (in aqueous solution) versus alcohol, Outcome 1 Catheter-
related BSI.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 5 Chlorhexidine (in aqueous solution) versus alcohol
Outcome: 1 Catheter-related BSI
Study or subgroup Chlorhexidine-based Alcohol based Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maki 1991 1/67 2/32 100.0 % 0.24 [ 0.02, 2.54 ]
Total (95% CI) 67 32 100.0 % 0.24 [ 0.02, 2.54 ]
Total events: 1 (Chlorhexidine-based), 2 (Alcohol based)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chlorhexidine Favours povidone-iodine
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Analysis 5.2. Comparison 5 Chlorhexidine (in aqueous solution) versus alcohol, Outcome 2 Catheter
colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 5 Chlorhexidine (in aqueous solution) versus alcohol
Outcome: 2 Catheter colonisation
Study or subgroup Chlorhexidine-based Alcohol-based Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maki 1991 4/67 5/32 100.0 % 0.38 [ 0.11, 1.33 ]
Total (95% CI) 67 32 100.0 % 0.38 [ 0.11, 1.33 ]
Total events: 4 (Chlorhexidine-based), 5 (Alcohol-based)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alcohol Favours chlorhexidine
Analysis 6.1. Comparison 6 Povidone-iodine (in aqueous solution) versus alcohol, Outcome 1 Catheter-
related BSI.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 6 Povidone-iodine (in aqueous solution) versus alcohol
Outcome: 1 Catheter-related BSI
Study or subgroup
Povidone-
iodine-
based Alcohol-based Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maki 1991 5/77 2/32 100.0 % 1.04 [ 0.21, 5.08 ]
Total (95% CI) 77 32 100.0 % 1.04 [ 0.21, 5.08 ]
Total events: 5 (Povidone-iodine-based), 2 (Alcohol-based)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Alcohol Povidone-iodine
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Analysis 6.2. Comparison 6 Povidone-iodine (in aqueous solution) versus alcohol, Outcome 2 Catheter
colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 6 Povidone-iodine (in aqueous solution) versus alcohol
Outcome: 2 Catheter colonisation
Study or subgroup
Povidone-
iodine-
based Alcohol-based Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Povidone-iodine in aqueous solution versus alcohol
Maki 1991 15/77 5/32 93.4 % 1.25 [ 0.49, 3.14 ]
Subtotal (95% CI) 77 32 93.4 % 1.25 [ 0.49, 3.14 ]
Total events: 15 (Povidone-iodine-based), 5 (Alcohol-based)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
2 Povidone-iodine-impregnated adherent film versus alcohol
Levy 1988 4/30 0/30 6.6 % 9.00 [ 0.51, 160.17 ]
Subtotal (95% CI) 30 30 6.6 % 9.00 [ 0.51, 160.17 ]
Total events: 4 (Povidone-iodine-based), 0 (Alcohol-based)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 107 62 100.0 % 1.76 [ 0.76, 4.09 ]
Total events: 19 (Povidone-iodine-based), 5 (Alcohol-based)
Heterogeneity: Chi2 = 1.77, df = 1 (P = 0.18); I2 =43%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 1.64, df = 1 (P = 0.20), I2 =39%
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Analysis 7.1. Comparison 7 Alcohol versus octenidine in alcohol, Outcome 1 Catheter-related BSI.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 7 Alcohol versus octenidine in alcohol
Outcome: 1 Catheter-related BSI
Study or subgroup Alcohol-based Octenidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dettenkofer 2010 16/193 8/194 100.0 % 2.01 [ 0.88, 4.59 ]
Total (95% CI) 193 194 100.0 % 2.01 [ 0.88, 4.59 ]
Total events: 16 (Alcohol-based), 8 (Octenidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Alcohol versus octenidine in alcohol, Outcome 2 Catheter-related BSI per 1000
catheter-days.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 7 Alcohol versus octenidine in alcohol
Outcome: 2 Catheter-related BSI per 1000 catheter-days
Study or subgroup Alcohol-based Octenidine log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Dettenkofer 2010 193 194 0.78 (0.71) 100.0 % 2.18 [ 0.54, 8.77 ]
Total (95% CI) 193 194 100.0 % 2.18 [ 0.54, 8.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alcohol Favours octenidine
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Analysis 7.3. Comparison 7 Alcohol versus octenidine in alcohol, Outcome 3 Catheter colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 7 Alcohol versus octenidine in alcohol
Outcome: 3 Catheter colonisation
Study or subgroup Alcohol-based Octenidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dettenkofer 2010 28/157 13/165 100.0 % 2.26 [ 1.22, 4.21 ]
Total (95% CI) 157 165 100.0 % 2.26 [ 1.22, 4.21 ]
Total events: 28 (Alcohol-based), 13 (Octenidine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.0099)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alcohol-based Favours octenidine
Analysis 7.4. Comparison 7 Alcohol versus octenidine in alcohol, Outcome 4 Catheter colonisation per
1000 catheter-days.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 7 Alcohol versus octenidine in alcohol
Outcome: 4 Catheter colonisation per 1000 catheter-days
Study or subgroup Alcohol-based Octenidine log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Dettenkofer 2010 157 165 0.8 (0.53) 100.0 % 2.23 [ 0.79, 6.29 ]
Total (95% CI) 157 165 100.0 % 2.23 [ 0.79, 6.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alcohol Favours octenidine
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Analysis 7.5. Comparison 7 Alcohol versus octenidine in alcohol, Outcome 5 Skin colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 7 Alcohol versus octenidine in alcohol
Outcome: 5 Skin colonisation
Study or subgroup Alcohol-based Octenidine
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[mean
CFU] N
Mean(SD)[mean
CFU] IV,Fixed,95% CI IV,Fixed,95% CI
Dettenkofer 2010 178 100 (308.4) 187 21 (64.5) 100.0 % 79.00 [ 32.76, 125.24 ]
Total (95% CI) 178 187 100.0 % 79.00 [ 32.76, 125.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.00081)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Favours alcohol Favours octenidine
Analysis 7.6. Comparison 7 Alcohol versus octenidine in alcohol, Outcome 6 Adverse effects.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 7 Alcohol versus octenidine in alcohol
Outcome: 6 Adverse effects
Study or subgroup Alcohol-based Octenidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dettenkofer 2010 45/197 54/201 100.0 % 0.85 [ 0.60, 1.20 ]
Total (95% CI) 197 201 100.0 % 0.85 [ 0.60, 1.20 ]
Total events: 45 (Alcohol-based), 54 (Octenidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alcohol Favours octenidine
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Analysis 8.1. Comparison 8 Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus
chlorhexidine (in alcohol), Outcome 1 Catheter colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 8 Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus chlorhexidine (in alcohol)
Outcome: 1 Catheter colonisation
Study or subgroup CG and PI combined Chlorhexidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Langgartner 2004 2/43 11/45 100.0 % 0.19 [ 0.04, 0.81 ]
Total (95% CI) 43 45 100.0 % 0.19 [ 0.04, 0.81 ]
Total events: 2 (CG and PI combined), 11 (Chlorhexidine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CG-PI combination Favours chlorhexidine
Analysis 8.2. Comparison 8 Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus
chlorhexidine (in alcohol), Outcome 2 Catheter colonisation per 1000 catheter-days.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 8 Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus chlorhexidine (in alcohol)
Outcome: 2 Catheter colonisation per 1000 catheter-days
Study or subgroup CG and PI combined Chlorhexidine log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Langgartner 2004 43 45 -1.66 (0.58) 100.0 % 0.19 [ 0.06, 0.59 ]
Total (95% CI) 43 45 100.0 % 0.19 [ 0.06, 0.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours combined Favours Chlorhexidine
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Analysis 9.1. Comparison 9 Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus
povidone-iodine (in aqueous solution), Outcome 1 Catheter colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 9 Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus povidone-iodine (in aqueous solution)
Outcome: 1 Catheter colonisation
Study or subgroup CG and PI combined Povidone-iodine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Langgartner 2004 2/43 16/52 100.0 % 0.15 [ 0.04, 0.62 ]
Total (95% CI) 43 52 100.0 % 0.15 [ 0.04, 0.62 ]
Total events: 2 (CG and PI combined), 16 (Povidone-iodine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0088)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CG-PI combination Favours povidone-iodine
Analysis 9.2. Comparison 9 Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus
povidone-iodine (in aqueous solution), Outcome 2 Catheter colonisation per 1000 catheter-days.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 9 Chlorhexidine (in alcohol) plus povidone-iodine (in aqueous solution) versus povidone-iodine (in aqueous solution)
Outcome: 2 Catheter colonisation per 1000 catheter-days
Study or subgroup CG and PI combined Povidone-iodine log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Langgartner 2004 43 52 -1.79 (0.58) 100.0 % 0.17 [ 0.05, 0.52 ]
Total (95% CI) 43 52 100.0 % 0.17 [ 0.05, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours combined Favours povidone-iodine
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Analysis 10.1. Comparison 10 Sanosil (hydrogen peroxide and silver) versus water as adjunct to
chlorhexidine 2% aqueous bath plus povidone-iodine aqueous 10% scrub, Outcome 1 Catheter colonisation.
Review: Skin antisepsis for reducing central venous catheter-related infections
Comparison: 10 Sanosil (hydrogen peroxide and silver) versus water as adjunct to chlorhexidine 2% aqueous bath plus povidone-iodine aqueous 10% scrub
Outcome: 1 Catheter colonisation
Study or subgroup Sanosil Water Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yousefshahi 2013 26/113 29/136 100.0 % 1.08 [ 0.68, 1.72 ]
Total (95% CI) 113 136 100.0 % 1.08 [ 0.68, 1.72 ]
Total events: 26 (Sanosil), 29 (Water)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Sanosil Favours water
A P P E N D I C E S
Appendix 1. Glossary of terms (lay definitions in the context of this review only)
Colonisation: occupation by bacteria or other micro-organisms in a specific body part or a device in the body without causing infection
Erythema: redness
Induration: a term usually used to describe the hardening of a small area of the skin
Infusates: liquid that is being infused through a device, such as a line, from the source (such as the fluid bag) to the patient
Nosocomial infection: also known as a hospital-acquired infection orHAI, an infection whose development is favoured by a hospital
environment, such as one acquired by a patient during a hospital visit or one developed among hospital staff. Such infections include
fungal and bacterial infections and are aggravated by the reduced resistance of individual patients.
Pathogenesis: the chain of events leading to the appearance of a disease or a medical problem, described scientifically in detail
Placebo: a simulated or ’sham’ treatment that is designed to be indistinguishable from the actual treatment in all aspects except for the
active component tested
Plasmapheresis: a medical procedure in which a person’s blood is channeled out of his body to a special ’filtering machine’ and then
returned to the body after the removal of the unwanted substance. It is used to treat a variety of medical problems in which unwanted
substances, usually in the form of harmful antibodies, are produced
Purulence: the state where pus appears at or around a lesion such as a wound
Regimen: a systematic plan of single or multiple measures designed to improve the health of a patient
Single agent: the use of only one antiseptic agent
A combination of agents: the use of more than one antiseptic agent together
Transient flora: bacteria that occupy a specific place in the body or a device for a short-term period
Subclavian vein: large blood vessels on each the side of the neck; commonly used as a site for inserting a central venous catheter.
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Appendix 2. Definitions of infections linked to vascular access
Table 1. Definitions of infections linked to vascular access (Pagani 2008)
Type of infection Criteria
Catheter colonisation A significant growth of amicro-organism (> 15CFU) from the catheter tip, subcutaneous
segment or catheter hub in the absence of clinical signs of infection
Exit-site/insertion site infection Microbiologically documented: exudates at catheter exit site yield a micro-organism
with or without concomitant bloodstream infection. Clinically documented: erythema
or induration within 2 cm of the catheter insertion site in the absence of associated
bloodstream infection and without concomitant purulence
Positive blood culture Micro-organism, potentially pathogenic, cultured from one or more blood culture
Bloodstream infection Positive blood culture with a clinical sepsis (see below)
Primary bloodstream infection Laboratory-confirmed bloodstream infection or clinical sepsis occurring without docu-
mented infection
Secondary bloodstream infection Laboratory-confirmed bloodstream infection secondary to another documented infec-
tion
Clinical sepsis Requires one of the following with no other recognised cause: fever (> 38° C), hypoten-
sion (SBP < 90 mmHg), oliguria (< 20 ml/h); and all of the following: blood culture
not performed or no organism detected in blood, no apparent infection at another body
site and clinical response to therapy following catheter removal or change
Catheter-associated bloodstream infection Primary bloodstream infection or clinical sepsis in the presence of an intravascular device
Catheter-related bloodstream infection Laboratory-confirmed bloodstream infection in the presence of an intravascular access:
at least 1 positive blood culture obtained from a peripheral vein, clinical manifestation
of infection and no apparent source of the bloodstream infection except the vascular
access, and with 1 of the microbiological methods: a positive result of semi-quantitative
(> 15 CFUs per catheter segment) or quantitative culture (> 103 CFU/catheter segment)
with the same organism, paired quantitative blood cultures with a > 5:1 ratio device
versus peripheral, differential time to positivity (blood culture obtained from a CVC is
positive at least 2 h earlier than a peripheral blood culture)
CFU: colony-forming units; CVC: central venous catheter; S BP: systolic blood pressure.
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Appendix 3. The Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
#1 MeSH descriptor: [Catheterization, Central Venous] explode all trees
#2 central next venous next catheter*:ti,ab,kw
#3 central next venous next line*:ti,ab,kw
#4 {or #1-#3}
#5 MeSH descriptor: [Antisepsis] explode all trees
#6 antisepsis:ti,ab,kw
#7 MeSH descriptor: [Hand Hygiene] explode all trees
#8 (handwash* or hand wash* or “hand hygiene”):ti,ab,kw
#9 aseptic next technique*:ti,ab,kw
#10 barrier next precaution*:ti,ab,kw
#11 MeSH descriptor: [Anti-Infective Agents, Local] explode all trees
#12 MeSH descriptor: [Chlorhexidine] explode all trees
#13 MeSH descriptor: [Iodine] explode all trees
#14 MeSH descriptor: [Povidone] explode all trees
#15 MeSH descriptor: [Triclosan] explode all trees
#16 MeSH descriptor: [Hexachlorophene] explode all trees
#17 MeSH descriptor: [Cetrimonium Compounds] explode all trees
#18 MeSH descriptor: [Phenol] explode all trees
#19 MeSH descriptor: [Hydrogen Peroxide] explode all trees
#20 MeSH descriptor: [Alcohols] explode all trees
#21 MeSH descriptor: [Soaps] explode all trees
#22 (iodine* or povidone* or chlorhexidine or betadine or triclosan or hexachlorophene or chloroxylenol or cetrimide or benzalkonium
or benzylkonium or octenidine or phenol* or carbolic or “hydrogen peroxide” or alcohol or alcohols or antiseptic* or soap*):ti,ab,kw
#23 skin near/3 disinfect*:ti,ab,kw
#24 {or #5-#23}
#25 {and #4, #24} in Trials
Appendix 4. Ovid MEDLINE search strategy
1 exp Catheterization, Central Venous/
2 central venous catheter*.tw.
3 central venous line*.tw.
4 or/1-3
5 exp Antisepsis/
6 antisepsis.tw.
7 exp Hand Hygiene/
8 (handwash* or hand wash* or hand hygiene).tw.
9 aseptic technique*.tw.
10 barrier precaution*.tw.
11 exp Anti-Infective Agents, Local/
12 exp Chlorhexidine/
13 exp Iodine/
14 exp Povidone/
15 exp Triclosan/
16 exp Hexachlorophene/
17 exp Cetrimonium Compounds/
18 exp Phenol/
19 exp Hydrogen Peroxide/
20 exp Alcohols/
21 exp Soaps/
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22 (iodine* or povidone* or chlorhexidine or betadine or triclosan or hexachlorophene or chloroxylenol or cetrimide or benzalkonium
or benzylkonium or octenidine or phenol* or carbolic or hydrogen peroxide or alcohol or alcohols or antiseptic* or soap*).tw.
23 (skin adj3 disinfect*).tw.
24 or/5-23
25 4 and 24
26 randomized controlled trial.pt.
27 controlled clinical trial.pt.
28 randomi?ed.ab.
29 placebo.ab.
30 clinical trials as topic.sh.
31 randomly.ab.
32 trial.ti.
33 or/26-32
34 exp animals/ not humans.sh.
35 33 not 34
36 and/25,35
Appendix 5. Ovid EMBASE search strategy
1 exp central venous catheter/
2 central venous catheter*.tw.
3 central venous line*.tw.
4 or/1-3
5 exp antisepsis/
6 antisepsis.tw.
7 exp hand washing/
8 (handwash* or hand wash* or hand hygiene).tw.
9 aseptic technique*.tw.
10 barrier precaution*.tw.
11 exp topical antiinfective agent/
12 exp chlorhexidine/
13 exp iodine/
14 exp povidone/
15 exp povidone iodine/
16 exp triclosan/
17 exp hexachlorophene/
18 exp cetrimide/
19 exp benzalkonium/
20 exp octenidine/
21 exp phenol/
22 exp hydrogen peroxide/
23 exp alcohol/
24 exp soap/
25 (iodine* or povidone* or chlorhexidine or betadine or triclosan or hexachlorophene or chloroxylenol or cetrimide or benzalkonium
or benzylkonium or octenidine or phenol* or carbolic or hydrogen peroxide or alcohol or alcohols or antiseptic* or soap*).tw.
26 (skin adj3 disinfect*).tw.
27 or/5-26
28 4 and 27
29 Randomized controlled trials/
30 Single-Blind Method/
31 Double-Blind Method/
32 Crossover Procedure/
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33 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab.
34 (doubl$ adj blind$).ti,ab.
35 (singl$ adj blind$).ti,ab.
36 or/29-35
37 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
38 human/ or human cell/
39 and/37-38
40 37 not 39
41 36 not 40
42 28 and 41
Appendix 6. EBSCO CINAHL Plus search strategy
S1 (MH “Central Venous Catheters+”)
S2 (MH “Catheterization, Central Venous+”)
S3 TI central venous catheter* or AB central venous catheter*
S4 TI central venous line* or AB central venous line*
S5 S1 or S2 or S3 or S4
S6 TI antisepsis or AB antisepsis
S7 (MH “Handwashing+”)
S8 TI ( handwash* or hand wash* or hand hygiene ) or AB ( handwash* or hand wash* or hand hygiene )
S9 TI aseptic technique* or AB aseptic technique*
S10 TI barrier precaution* or AB barrier precaution*
S11 (MH “Antiinfective Agents, Local+”)
S12 (MH “Chlorhexidine”)
S13 (MH “Iodine”)
S14 (MH “Povidone-Iodine”)
S15 (MH “Hexachlorophene”)
S16 (MH “Benzalkonium Compounds”)
S17 (MH “Phenols”)
S18 (MH “Hydrogen Peroxide”)
S19 (MH “Alcohols+”)
S20 (MH “Soaps”)
S21TI iodine* or povidone* or chlorhexidine or betadine or triclosan or hexachlorophene or chloroxylenol or cetrimide or benzalkonium
or benzylkonium or octenidine or phenol* or carbolic or hydrogen peroxide or alcohol or alcohols or antiseptic* or soap*
S22AB iodine* or povidone* or chlorhexidine or betadine or triclosan or hexachlorophene or chloroxylenol or cetrimide or benzalkonium
or benzylkonium or octenidine or phenol* or carbolic or hydrogen peroxide or alcohol or alcohols or antiseptic* or soap*
S23 TI skin N3 disinfect* or AB skin N3 disinfect*
S24 S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23
S25 S5 and S24
S26 MH “Clinical Trials+”
S27 PT Clinical trial
S28 TI clinic* N1 trial* or AB clinic* N1 trial*
S29 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S30 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S31 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S32 MH “Random Assignment”
S33 TI random* allocat* or AB random* allocat*
S34 MH “Placebos”
S35 TI placebo* or AB placebo*
S36 MH “Quantitative Studies”
S37 S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36
90Skin antisepsis for reducing central venous catheter-related infections (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S38 S25 and S37
Appendix 7. Risk of bias criteria
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes used without appropriate
safeguards (e.g. envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record
number; any other explicitly unconcealed procedure.
Unclear
Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not
described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described,
but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following:
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
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• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others unlikely to introduce bias.
High risk of bias
Any one of the following:
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Unclear
Any one of the following:
• Insufficient information to permit judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following:
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a
clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Either of the following:
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes enough to induce clinically relevant bias in observed effect size.
• ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Any one of the following:
• Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated,
no reasons for missing data provided).
• The study did not address this outcome.
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5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following:
• The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the
review have been reported in the prespecified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were prespecified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following:
• Not all of the study’s prespecified primary outcomes have been reported.
• One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
were not prespecified.
• One or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as
an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used;
• had extreme baseline imbalance;
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. We have amended the title of the review by omitting the phrase “during catheter insertion”. This was considered appropriate as
all of our included studies examined skin antisepsis throughout the in-dwelling period of the catheters with or without including the
period of insertion, and keeping the phrase “during catheter insertion” would be misleading. We have revised the text of our review
from Background through to the Methods where appropriate to reflect the change.
2. Under ’Why it is important to do this review’, we changed the original statements “However, in some studies within themeta-analysis,
a combination of antiseptics were used; for example, chlorhexidine gluconate was sometimes evaluated in combination with alcohol.
There remain some uncertainties regarding the best agent or combination of agents to be used for skin antisepsis” to the following:
“However, the meta-analysis only evaluated chlorhexidine gluconate and povidone-iodine as skin antiseptics, and some studies within
it assessed a combination of arterial catheters as well as central and peripheral venous catheters. Some uncertainties remain regarding
the best agent, or combination of agents, for use as skin antisepsis for CVCs alone . . .”. This was because in this review, the studies
included also used a combination of agents, and there were no studies that assessed chlorhexidine gluconate separately, so the original
statements did not justify the need for this review. Instead, the new statements more clearly reflect the differences between this review
and the earlier review mentioned.
3. Under ’Types of studies’, we added the following statements to further define the scope of our selection of studies: “We excluded
cross-over studies due to the possible contaminating effect of one intervention over another. We also excluded studies assessing CVCs
for haemodialysis, as this is covered by another Cochrane review (McCann 2010).”
4. Under ’Selection of studies’, we omitted the reference to unpublished studies because we did not find any unpublished study in our
search of the trials registries.
5. Under Electronic searches, we updated the CENTRAL and MEDLINE search strategies in line with the updated indexing terms in
each database.
6. Under ’Data extraction and management’, we have re-written paragraph 2 to the following to reflect what was actually done in the
review.
“We found a discrepancy between the number of catheter and the number of patients in most studies, and this was due to multiple
catheters being enrolled in some patients. However, we were unable to limit our analysis to one catheter per participant as none of the
individual studies provided the adjusted results based on one catheter per participant.”
7. We have added the section ’Unit of analysis issues’ to describe how we would handle cluster-RCTs.
8. Under ’Dealing with missing data’, we revised our statement to include the absolute dropout rate in our consideration in assessing
the risk of attrition bias, as a number of included studies had very high absolute dropout rates. Our revised statements are shown below:
“To assess whether the dropout rate was significant, we inspected the absolute dropout rate and the dropout rate in relation to the event
rates for the intervention and the comparison groups. If the absolute dropout rate was 20% or more, we judged the study to be at high
risk for incomplete outcome data. If the dropout rate was lower than 20%, we used a ’worst-case-scenario’ method . . .”
9. Under ’Assessment of heterogeneity’, we revised the statement to reflect what was actually done in the review, as follows:
“We found significant statistical heterogeneity in one analysis (Analysis 4.4) and provided a plausible explanation the possible reason
for heterogeneity in the form of risk of attrition bias in some included studies. We decided to still provided the pooled estimate for this
analysis and separated the studies based on the risk of attrition bias in our pre-specified sensitivity analysis.”
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10. Under ’Sensitivity analysis’, we re-wrote the section as follows to reflect the information that we gathered in the review and removed
any mention of intention-to-treat analysis:
“We performed the following sensitivity analyses.
1. Best- and worst-case scenarios to assess the impact of missing data, as described in the section ’Dealing with missing data’.
2. Including and excluding studies with unclear and high risks of selection bias, namely, studies with unclear or high risk for
random sequence generation, allocation concealment or both.
Had sufficient data been available, we would have performed additional sensitivity analyses to include and exclude studies with
methodological issues other than selection bias, such as a lack of blinding to the participants, care givers or investigators, or where
blinding was unclear.”
11. Under ’Subgroup analysis and investigation of heterogeneity’, we added the following statement to describe the separation of
comparisons into subgroups based on the solution used, in response to the referees’ comments in our draft review:
“In this review, we created subgroups of comparisons based on the solution used, for example, a subgroup for chlorhexidine in aqueous
solution versus povidone iodine in aqueous solution, and another subgroup for chlorhexidine in alcohol versus povidone-iodine in
aqueous solution.”
I N D E X T E R M S
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